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SUBARACHNOID HEMORRHAGE 
 
Sheila Alexander, PhD 
 
University of Pittsburgh, 2004 
 
ABSTRACT 
 
Subarachnoid hemorrhage (SAH) is a hemorrhagic stroke subtype affecting 30,000 Americans 
per year.  The most common cause of secondary injury after SAH is cerebral vasospasm (CV).  
Currently, there are no biomarkers to identify risk for CV.  Apolipoprotein E (apoE) is a protein 
with potential to alter tone of cerebral vessels by influencing intracellular calcium homeostasis.  
ApoE has isoform specific effects on intracellular calcium (Ca++) level, cerebral vessel tone, and 
potentially CV.  The overall objective of this project was to describe the relationship between 
apoE genotype (APOE), apoE protein level, calcium level and presence of CV after SAH.  This 
study included individuals age 18-75 with a diagnosis of severe SAH from an aneurysmal 
source.  Daily cerebrospinal fluid samples were drawn from a drainage catheter.  APOE 
genotyping was performed using standard restriction fragment length polymorphism techniques.   
The sample was dichotomized based on APOE ε4 allele presence.  Daily apoE protein levels 
were analyzed using an enzyme linked immunoassay.  Ca++ level was analyzed using 
potentiometry.  CV was verified using cerebral angiogram, computed tomographic angiogram, or 
elevated transcranial dopplers the entire group were lower than normal and associated with one 
another.  Overall and daily apoE protein levels were higher in individuals with an APOE ε4 
allele but there was no association with CV.  Overall Ca++ level was higher in the individuals 
without CV, however daily mean was not significantly different between the two CV groups.  
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Overall and daily mean Ca++ levels were higher in individuals with an APOE ε4 allele.   This 
project further describes the relationship between apoE, Ca++ and neurologic disease, however 
more work is required before either CSF apoE or Ca++ can be used as a predictor of CV.  
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1. INTRODUCTION 
 
1.1. SUBARACHNOID HEMORRHAGE 
Subarachnoid hemorrhage (SAH) is an emergent condition characterized by the presence of 
blood in the subarachnoid space, primarily resulting from a ruptured cerebral aneurysm or 
arterio-venous malformation.  Approximately 50% of individuals surviving the initial 
hemorrhage will succumb to a secondary insult (Saito, Ueda et al. 1977).  The most common 
condition resulting in secondary insult is cerebral vasospasm (CV), with 30 to 60 percent of 
people with SAH developing secondary CV (Kassell 1985; Ohman 1991; Solenski 1995).  CV is 
a narrowing of the lumen of the cerebral blood vessels that causes a decrease in cerebral blood 
flow to the associated brain tissue.  As CV progresses, there is a decrease in the delivery of 
oxygen and nutrients to the brain resulting in increased risk of cerebral ischemia.  Occurrence 
and severity of CV has been associated with amount and location of blood on initial computed 
tomography (CT) scan after SAH (Fisher, Kistler et al. 1980).  The breakdown of blood in the 
subarachnoid space following SAH releases oxyhemoglobin-derived free radicals which can 
inhibit the adenosine triphosphate (ATP)-dependent calcium pump (Fujii and Fujitsu 1988; 
Macdonald 1991; Macdonald, Weir et al. 1991) and lead to CV.   
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1.2. CALCIUM HOMEOSTASIS 
1.2.1. Primary Pathway 
The ATP-dependent calcium (Ca ) pump is the primary pathway that maintains intracellular++  
Ca homeostasis in vascular smooth muscle cells.  Nerve cell stimulation and subsequent muscle 
cell membrane depolarization results in the movement of charge down the muscle cells’ 
membrane and stimulation of the transverse tubules, a series of folds in the membrane.  The 
potential then moves across the cytosol in the cell to the sarcoplasmic reticulum where large 
++ 
Ca++ 
channels are stimulated to open and release Ca++ into the cytosol.  When the cytosolic Ca++ 
elevates to a level >10-5 M low-affinity, high-capacity Ca++ pumps in the inner mitochondrial 
membrane and/or the sarcoplasmic reticulum take up additional Ca++ (Alberts, Bray et al. 1994).   
This ATP-dependent calcium pump is the primary method of decreasing cytosolic Ca++ in 
vascular smooth muscle cells (Alberts, Bray et al. 1994).  The contractile activity of vascular 
smooth muscle is regulated by the concentration of cytosolic Ca++ (Alberts, Bray et al. 1994).  
An increase in cytosolic Ca++ leads to the shortening of myofibrils within the cell and subsequent 
cellular contraction (Alberts, Bray et al. 1994).  Contraction of adjacent cells within a section of 
an artery decreases the internal lumen of the vessel and is known as vasospasm.  When this 
primary method of cytosolic Ca++ maintenance is impaired, secondary pathways take over much 
of the responsibility of Ca++ maintenance.  
1.2.2. Secondary Pathways 
There are three main secondary cytosolic Ca++ pathways: 1) the Na+/Ca++ exchanger, 2) ligand 
gated Ca++ channels, and 3) G-protein linked receptors (Alberts, Bray et al. 1994).  The Na+/Ca++ 
exchanger is an antiporter system that requires a protein located in cell plasma membranes to 
export Ca++ in exchange for Na+.  This protein is a Ca++ pump driven by the Na+ electrochemical 
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gradient.  The pump requires that Na+ move into the cell as the Ca++ is pumped out (Alberts, 
Bray et al. 1994).   
There are over 100 different ligands that open Ca++ channels (Alberts, Bray et al. 1994).  
The receptor on the Ca++ channel of the plasma membrane has a series of amino acids on its 
binding site that form weak bonds with the ligand(s), which change the shape of the original Ca++ 
channel.  This causes the Ca++ channel to open (Alberts, Bray et al. 1994) and move extracellular 
Ca++ inward increasing cytosolic Ca++ (Tolar, Keller et al. 1999).  
The third secondary pathway, the trimeric guanisine triphosphate-binding regulatory protein 
(G-protein) linked-receptors, indirectly regulates plasma membrane activities.  A variety of 
molecules (i.e. acetylcholine) interact with their receptors, triggering activation of a mediating 
protein, a G-protein (Alberts, Bray et al. 1994).   Activation of G-protein can alter ion 
permeability of the plasma membrane or stimulate other intracellular mediators that alter the 
behavior of subsequent proteins (Alberts, Bray et al. 1994).  The end result is opening of Ca++ 
channels in the plasma membrane and in the sarcoplasmic reticulum allowing for increasing 
cytosolic Ca++ level (Alberts, Bray et al. 1994).   
1.2.3. Apolipoprotein E and Calcium 
Apolipoprotein E (apoE) influences intracellular Ca++ through a G-protein pathway.  ApoE 
protein attachment to a G-protein linked receptor on the cell surface results in an influx of 
extracellular Ca++ into the cytosol (Veinbergs, Everson et al. 2002).  When the primary method 
of cytosolic homeostasis (the ATP-dependent Ca++ pump) is inhibited, the role of secondary 
pathways on Ca++ homeostasis, including that of the apoE associated G-protein pathway, 
becomes more dominant.   
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1.3. APOE FUNCTION 
Historically, apoE has been described primarily as a lipid clearance and metabolic protein.   
ApoE also has been associated with maintenance of cellular membranes (Hayashi, Igbavboa et 
al. 2002), (Mahley 1988; Weisgraber, Roses et al. 1994), control of enzyme activity (Reyland, 
Gwynne et al. 1991), immunoregulation (Pepe and Curtiss 1986), neuronal plasticity (Nathan, 
Bellosta et al. 1994; Nathan, Jiang et al. 2002) and cytosolic calcium level maintenance (Muller, 
Meske et al. 1998; Tolar, Keller et al. 1999; Veinbergs, Everson et al. 2002).  ApoE is present in 
highest concentration in the liver where the majority of lipid maintenance activities occur, 
however the second highest concentration of apoE is in the brain. 
There are three apoE protein isoforms (apoE2, apoE3, and apoE4) that differ in their 
amino acid sequences and structure that reportedly can impact lipid clearance (Utermann, 
Kindermann et al. 1984).  ApoE4 protein is less effective at lipid clearance resulting in increased 
plasma cholesterol while the apoE2 protein is more effective at clearing lipids and thereby 
decreasing plasma cholesterol (Utermann, Kindermann et al. 1984).     Differential effects of the 
apoE2 protein, as compared to the E3 or E4 proteins, in the nervous system are not well 
documented.  The apoE4 protein, when compared to the E3 isoform, is linked with increased 
lipid peroxidation and increased oxidative injury (Nathan, Bellosta et al. 1994; Holtzman, Pitas 
et al. 1995; Fagan, Bu et al. 1996; Ma, Brewer et al. 1996; Miyata and Smith 1996; Laskowitz, 
Sheng et al. 1997; DeMattos, Curtiss et al. 1998; Jordan, Galindo et al. 1998; Sun, Wu et al. 
1998; Horsburgh, Kelly et al. 1999; Montine, Olson et al. 1999; Sheng, Laskowitz et al. 1999; 
Teter, Xu et al. 1999), decreased neuronal plasticity (Ignatius, Gebicke-Harter et al. 1986; 
Poirier, Hess et al. 1991; Poirier, Baccichet et al. 1993), and interacts with amyloid beta in a 
manner that is associated with a less favorable outcome in neurons (Namba, Tomonaga et al. 
1991; LaDu, Falduto et al. 1994; LaDu, Pederson et al. 1995; Beffert, Danik et al. 1998).  In 
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addition, the apoE4 protein also is associated with increased neurotoxicity (Marques, Tolar et al. 
1996; Michikawa and Yanagisawa 1998; Moulder, Narita et al. 1999).  This neurotoxicity is 
associated with a G-protein linked influx of Ca++ from the extracellular space.  The Ca++ influx 
associated with apoE is dose dependent, with increased influx associated with increased apoE 
level (Veinbergs, Everson et al. 2002).  Further, the influx is greater when the apoE 4 isoform is 
present in the extracellular space as compared to apoE3 (Veinbergs, Everson et al. 2002).  This 
influx of Ca++ is sustained and nonreversible (Veinbergs, Everson et al. 2002).  Given that the 
contractile activity of vascular smooth muscle is associated with increased neurotoxicity 
(Crutcher, Clay et al. 1994; Marques, Tolar et al. 1996), regulated by cytosolic Ca++ 
concentration, Ca++ influx associated with apoE, particularly the apoE4 isoform, could lead to 
CV.  
 
1.4. PURPOSE 
The purpose of this study was to examine the patterns of apolipoprotein E total and apoE4 
isoform specific protein expression relative to Ca++ levels in individuals with and without CV 
after SAH. 
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1.5. SPECIFIC AIMS 
1.  Describe the total and apoE4 isoform-specific CSF apoE protein expression, in relation to 
APOE genotype, of individuals with and without CV over time for the first 1-14 days after SAH. 
2.   Compare CSF Ca++ levels, in relation to APOE genotype, of individuals with and without CV 
over time for the first 1-14 days after SAH. 
3.  Compare the relationship between Ca++ levels and apoE (genotype and protein) in CSF of 
individuals with and without CV over time for the first 1-14 days after SAH.   
 
1.6. RESEARCH QUESTIONS/HYPOTHESIS 
1.  Is there a difference in total apoE and apoE4 isoform-specific protein expression, in relation 
to APOE4 genotype, in CSF 1-14 days after SAH in individuals with and without CV? 
2. Is there a difference in Ca++ levels, in relation to APOE4 genotype, in the CSF 1-14 days after 
SAH in individuals with and without CV? 
3. Is there a difference in the relationship between total apoE and apoE4 isoform-specific protein 
expression and Ca++ level in the CSF 1-14 days after SAH in individuals with and without CV 
after controlling for APOE genotype? 
 
1.7. DEFINITION OF TERMS  
1.7.1. Independent variables 
1.7.1.1. Cerebral vasospasm.  A decrease in external lumen size of the cerebral blood vessels 
will be determined via angiogram or computed tomography angiogram.  A neurosurgeon or 
 15
neuroradiologist coded the cerebral artery narrowing. CV group status was based on presence:  
CV positive and CV negative.  
1.7.1.2. APOE genotype.  Based on their genetic code, each individual was classified into 
one of 6 possible genotypes:  ε2/ε2, ε2/ε3, ε2/ε4, ε3/ε3, ε3/ε4, and ε4/ε4.  Genotype was 
dichotomized into two groups based on APOE ε4 allele presence: APOE4 positive and APOE4 
negative. 
1.7.2. Dependent Variables 
1.7.2.1.   ApoE protein expression.  When an individual is homozygous (i.e. ε2/ε2, ε3/ε3, 
ε4/ε4), the isoform specific apoE protein produced by the gene is 100% representative of the 
associated allele.    However, when an individual is heterozygous (i.e. ε2/ε3 or ε2/ε4), two 
different proteins are produced representing the two alleles in an unknown ratio.  ApoE protein 
levels were quantified daily by total apoE protein expressed and by the isoform ratio relative to 
the APOE allele pair. 
1.7.2.2. Calcium level.  The level of Ca++ in the CSF as measured in meq/L.   The average 
CSF calcium level in humans is about 2.1 meq/L (Kandel and Schwartz 1991).  Currently, CSF 
Ca++ level after SAH or associated with CV is unknown.  
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1.8. CONCEPTUALIZATION 
 
 
Figure 1. Model of study variables 
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 2. BACKGROUND AND SIGNIFICANCE 
 
2.1. SUBARACHNOID HEMORRHAGE 
Aneurysmal SAH afflicts 30,000 Americans per year (Mayberg, Batjer et al. 1994) with only 
50% surviving the initial hemorrhage (Newell, Grady et al. 1990).  SAH most commonly occurs 
when a cerebral aneurysm, a weakened and bulging (ballooning) wall of a blood vessel, ruptures 
releasing blood into the subarachnoid space.  Despite progress in standardizing treatment of SAH 
over the last 3 decades, the outcome of patients experiencing SAH remains poor (Ronkainen 
1999) with a disability rate of 50-70% (Dorsch and King 1994). Less than one-half of survivors 
of the initial SAH recover to their pre-hemorrhage neurological state by the first year after insult 
(Dorsch and King 1994).  Secondary injuries from complications of SAH include cerebral 
edema, increased intracranial pressure (ICP), clot, mass effect, and CV.  They affect over 50% of 
the patients (Saito, Ueda et al. 1977) and can lead to hypoxia and ischemia increasing the risk of 
morbidity and mortality.   
2.1.1. Primary Complication of SAH: Cerebral Vasospasm 
CV, the prolonged contraction of cerebral vascular smooth muscle cells, is the most common 
complication of SAH occurring in 50% of patients (Newell, Grady et al. 1990).  It can decrease 
delivery of blood to the brain and is associated with increased risk of cerebral ischemia, leading 
to increased morbidity and mortality (Kassell and Torner 1983; Weir 1995).  The onset of CV 
occurs most often between day 3 and day 9 post-SAH (Dorsch and King 1994; Cook 1995; Weir 
1995).  The primary risk factor for CV is increased blood volume in the ventricles and 
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subarachnoid space (Fisher, Kistler et al. 1980).  Investigations of agents responsible for CV 
focus primarily on molecular constituents released from the clot after SAH that may directly or 
indirectly alter vasoconstriction and/or dilation regulatory mechanisms of the cerebral 
vasculature (Dorsch and King 1994; Cook 1995).   
2.1.2. Pathophysiology of CV 
Following rupture of a cerebral aneurysm, blood enters the cerebrospinal fluid (CSF) in the 
subarachnoid space surrounding the cerebral vessels.  As red blood cells of the resultant clot lyse 
and breakdown, the oxygen-bound hemoglobin contained in those cells is released into the CSF 
(Fujii and Fujitsu 1988; Macdonald, Weir et al. 1991).  The unbound hemoglobin generates other 
reactive oxygen species (Fujii and Fujitsu 1988; Macdonald, Weir et al. 1991).  The presence of 
oxyhemoglobin-derived free radicals disrupts the primary intracellular Ca++ homoeostasis 
mechanism (Fujii and Fujitsu 1988; Macdonald 1991; Macdonald, Weir et al. 1991).  Wang and 
associates (1994) found that in a canine model of experimentally induced SAH, the activity of 
the adenosine triphosphatase (ATP)-dependent Ca++ pump (the primary method of intracellular 
Ca++ homoeostasis) initially increased, but this activity significantly decreased within 24 hours 
(Wang, Ohta et al. 1994).  Although the mechanism for the relationship between this process of 
elevating intracellular Ca++ and CV remains uncertain, there is evidence that CV begins with 
smooth muscle contraction initiated by increased and sustained intracellular Ca++ levels 
(Vollrath, Weir et al. 1990; Kim, Kim et al. 1999).  Kim et al, 1996, suggested from their animal 
model work that increased intracellular Ca++ levels were linked to CV (Kim, Wier et al. 1996). 
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2.2. The Role of Intracellular Ca++ in Vascular Contraction 
The contractile activity of vascular smooth muscle is regulated by cytosolic Ca++ concentration 
(Alberts, Bray et al. 1994). An increase in cytosolic Ca++ shortens myofibrils within the cell 
causing cellular contraction (Alberts, Bray et al. 1994).  Contraction of adjacent cells within a 
section of an artery decreases the internal lumen of the vessel resulting in vasospasm.   
2.2.1. Primary Ca++ Homeostasis Pathway 
The ATP-dependent Ca++ pump is the primary pathway maintaining intracellular Ca++ 
homeostasis in vascular smooth muscle cells (Pyne, Cadoux-Hudson et al. 2001).  Nerve cell 
stimulation depolarizes the membrane of a muscle cell, which stimulates the transverse tubules, a 
series of folds in the membrane.  The action potential stimulates the sarcoplasmic reticulum to 
open large Ca++ channels, which release Ca++ into the cytosol.  When cytosolic Ca++ elevates to a 
level greater than 10-5 M, low-affinity, high-capacity Ca++ pumps in the inner mitochondrial 
membrane and/or the sarcoplasmic reticulum are activated to remove additional Ca++ from the 
cytosol (Alberts, Bray et al. 1994).  (See figure 2.) This ATP-dependent Ca++ pump, while being 
the primary method of maintaining cytosolic Ca++ level, is not believed to play a major role in 
the initiation or maintenance of CV after SAH (Cook 1995).  Using patch clamp techniques in 
smooth muscle cells from rat basilar artery, Kim et al (1996) found that hemolysate reduced the 
amplitude of the L-type Ca++ current (ATP-dependent Ca++ channels) (Kim, Wier et al. 1996).  
This lowering of intracellular Ca++ levels indicates that the increased intracellular Ca++ 
associated with CV is related to a mechanism other than the ATP-dependent Ca++ channels.   
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Figure 2.  Intracellular calcium homeostasis 
2.2.2. Secondary Ca++ Homeostasis Pathways 
When this primary method of cytosolic Ca++ maintenance is impaired, the role of secondary 
pathways in cytosolic Ca++ maintenance is more influential.  The three principal secondary 
cytosolic Ca++ pathways are a) the Na+/Ca++ exchanger, b) ligand-gated Ca++ channels and c) G-
protein linked receptors (Alberts, Bray et al. 1994).    
The Na+/Ca++ exchanger is an antiporter system that requires a plasma membrane protein 
to export Ca++ in exchange for Na+.  This Ca++ pump is driven by the Na+ electrochemical 
gradient and requires that Na+ moves into the cell as Ca++ is pumped out, expending one to two-
thirds of a cells energy (Alberts, Bray et al. 1994).   
A series of amino acids on the cellular plasma membrane serve as the Ca++ channel 
receptor.  When a second molecule (the ligand) forms weak bonds with these amino acids, the 
shape of the original Ca++ channel changes causing it to open (Alberts, Bray et al. 1994), move 
extracellular Ca++ inward and increase cytosolic Ca++ (Tolar, Keller et al. 1999).  Nimodipine 
(Nimotop), a Ca++ channel blocker, is routinely administered to patients after SAH to mediate the 
specific effects of these ligands and prevent CV (Barker and Ogilvy 1996; Dorsch 1998; van 
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Gijn and Rinkel 2001).  Despite the routine administration of this medication, CV persists as the 
most common cause of morbidity and mortality after SAH (Dorsch 1998).  There are over 100 
ligands that reportedly open Ca++ channels (Alberts, Bray et al. 1994) yet no single ligand related 
medication has successfully eliminated the risk of CV after SAH. 
Trimeric GTP-binding regulatory protein (G-protein) linked-receptors indirectly regulate 
plasma membrane activities.  A variety of molecules (i.e. acetylcholine) interact with their 
receptors, triggering activation of a mediating protein called a G-protein.  Activation of G-
protein can alter ion permeability of the plasma membrane directly or stimulate other 
intracellular mediators.  This sets off a chain reaction that opens Ca++ channels in both the 
plasma membrane and sarcoplasmic reticulum and increases cytosolic Ca++ level (Alberts, Bray 
et al. 1994). 
One such G-protein linked pathway is activated by apolipoprotein E (apoE).  ApoE 
attaches to a receptor on the cell surface that activates a G-protein.  (See figure 3.)    This 
stimulates the opening of Ca++ channels and the influx of extracellular Ca++ into the cytosol 
(Wang, Gruenstein et al. 1997; Veinbergs, Everson et al. 2002).  Veinbergs and associates (2002) 
found that when mouse hippocampal cell lines were exposed to extracellular apoE, intracellular 
Ca++ increased from an extracellular source and intracellular Ca++ clearance was impaired 
(Veinbergs, Everson et al. 2002).  This suggests that when the ATP-dependent Ca++ pump is 
inhibited the influence of the apoE G-protein pathway, as well as other secondary pathways, on 
Ca++ homeostasis and vascular muscle tone becomes more dominant.  Minimal investigation of 
this secondary pathway in relation to the development of CV has been conducted.   
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Figure 3.  Hypothesized role of apoE in intracellular calcium homeostasis 
 
2.3. APOE GENOTYPE-PHENOTYPE 
Evidence shows that one’s genetic profile predisposes individuals to variations in both the 
development and response to treatment for neurologic diseases (Mahley, Nathan et al. 1996).  
Potential genetic variants have been identified in the development of Alzheimer’s disease, 
Parkinson’s disease and other neurodegenerative processes (Saunders, Pericak-Vance et al. 1995; 
Kamboh, Ferrell et al. 1998; Becker 2001). Kojima and associates (1998) found the odds of 
developing aneurysmal SAH are significantly increased (42.1%) in individuals with a positive 
family history (Kojima, Nagasawa et al. 1998).  The little work that has been done to study the 
impact of genetic influences on cerebral aneurysm formation supports a genetic susceptibility to 
aneurysm development (Schievink 1997; Schievink 1998; Peters, Kassam et al. 1999; Peters, 
Kassam et al. 2001).   
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Genetic variation also has been implicated in response to recovery from other acute 
cerebral injuries such as traumatic brain injury (Strittmatter, Schmechel et al. 1993; Jordan, 
Relkin et al. 1997) (Friedman, Froom et al. 1999), and stroke (Laskowitz, Horsburgh et al. 1998; 
Sheng, Laskowitz et al. 1998; Sheng, Laskowitz et al. 1999).  For example, variation in APOE 
genotype has been associated with poorer prognosis after brain injury (McCarron, Muir et al. 
2000).   
Only two base changes in the APOE gene result in 3 common alleles with 6 associated 
genotypes (APOE ε2/2, ε2/3, ε2/4, ε3/3, ε3/4, ε4/4).  The base changes (codon change from 
CGC to TGC at position 112 in the ε2 allele versus the ε3 allele; codon change from TGC to 
CGC at codon 158 in the ε4 allele versus the ε3 allele) lead to amino acid alterations at positions 
112 and 158 respectively when the gene is translated into protein (Utermann, Kindermann et al. 
1984).  The APOE ε3 allele, the most common allele, is translated into a protein with cysteine at 
position 112 and arginine at position 158 (Utermann, Kindermann et al. 1984).  As compared to 
the APOE ε4 allele that translates arginine rather than cysteine at position 112, the APOE ε2 
allele translates cysteine rather than arginine at position 158 (Utermann, Kindermann et al. 1984; 
Weisgraber 1994).  Allele frequencies in the general population of the United States are 
approximately 8% for ε2, 75% for ε3, and 15% for ε4 (Weisgraber 1994), although distribution 
frequencies differ based on ethnicity.   
The APOE ε4 allele also has been associated with increased risk for Alzheimer’s disease 
(Saunders, Pericak-Vance et al. 1995; Kamboh, Ferrell et al. 1998), schizophrenia (Martorell, 
Virgos et al. 2001; Hata, Kunugi et al. 2002), poorer recovery from traumatic brain injury 
(Jordan, Relkin et al. 1997; Friedman, Froom et al. 1999), cerebral ischemia (Laskowitz, 
Horsburgh et al. 1998; Sheng, Laskowitz et al. 1998; Sheng, Laskowitz et al. 1999), and 
 24
increased cognitive impairment related to time spent on cardio-pulmonary bypass machine 
during cardiac surgery (Chey, Kim et al. 2000; Kutner, Erlanger et al. 2000). In contrast the 
APOE ε2 allele has been associated with increased risk for cerebral amyloid angiopathy-related 
hemorrhage- a specific type of intracerebral hemorrhage (Nicoll and McCarron 2001). 
ApoE is primarily viewed as a lipid clearance and metabolism protein.   Its functions 
include maintenance of cellular membranes (Hayashi, Igbavboa et al. 2002),(Mahley 1988; 
Weisgraber, Roses et al. 1994), control of enzyme activity (Reyland, Gwynne et al. 1991), 
immunoregulation (Pepe and Curtiss 1986), neuronal plasticity (Nathan, Bellosta et al. 1994; 
Nathan, Jiang et al. 2002) and cytosolic calcium level maintenance (Muller, Meske et al. 1998; 
Tolar, Keller et al. 1999; Veinbergs, Everson et al. 2002).  The highest concentrations of apoE 
are found in the liver where the majority of lipid maintenance activities occur, with the second 
highest levels in the brain. In the brain, the production and secretion of apoE by astrocytes 
increases in response to central nervous system injury (Lin, Duan et al. 1999; Duan, Gu et al. 
2000). 
Little work has been done to study the impact of genetic variance on recovery after SAH.  
Two studies independently found that presence of at least one copy of the APOE ε4 allele (i.e. 
APOE genotypes ε2/4, ε3/4, and ε4/4) was associated with poorer outcomes at 3 months after 
SAH (Niskakangas 2001; Leung, Poon et al. 2002).  Alternatively, Dunn et al (2001) did not find 
a significant association between APOE genotype and outcome from SAH, although the allelic 
distribution of the sample did not match that of the general population (Dunn, Stewart et al. 
2001).  No other work known to this investigator has been done to identify genetic biomarkers 
associated with development of CV or recovery from SAH. 
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2.4. APOE PROTEIN ISOFORM AND NEUROLOGIC DISEASE PROCESS 
Each allele codes for a single isoform of the apoE protein (apoE2, 3, or 4) resulting in 
structurally related differences in function.  For example, the apoE4 protein isoform is less 
effective at lipid clearance and increases plasma cholesterol (Utermann, Kindermann et al. 
1984).  Differential effects of the apoE2 protein, as compared to the E3 or E4 proteins, in the 
nervous system continue to emerge.  It is unclear whether the variations in neurologic disease 
development, progression and response to cerebral injury are related to differences in the 
structure, function, or amount of the protein expressed.  The apoE4 protein isoform has been 
linked with increased lipid peroxidation and increased oxidative injury (Ma, Brewer et al. 1996; 
Miyata and Smith 1996; Laskowitz, Sheng et al. 1997; Jordan, Galindo et al. 1998; Horsburgh, 
Kelly et al. 1999; Montine, Olson et al. 1999; Sheng, Laskowitz et al. 1999), increased 
cytoskeletal protein binding, decreased neurite outgrowth (Bellosta, Mahley et al. 1995) (Nathan, 
Bellosta et al. 1994; Holtzman, Pitas et al. 1995; Fagan, Bu et al. 1996; DeMattos, Curtiss et al. 
1998; Sun, Wu et al. 1998; Teter, Xu et al. 1999), decreased neuronal plasticity (Ignatius, 
Gebicke-Harter et al. 1986; Poirier, Hess et al. 1991; Poirier, Baccichet et al. 1993), increased 
neurotoxicity (Crutcher, Clay et al. 1994; Marques, Tolar et al. 1996; Tolar, Marques et al. 1997; 
Michikawa and Yanagisawa 1998; Moulder, Narita et al. 1999), and interaction with amyloid 
beta in a manner that is associated with a less favorable outcome in neurons (Namba, Tomonaga 
et al. 1991; LaDu, Falduto et al. 1994; LaDu, Pederson et al. 1995; Beffert, Danik et al. 1998).   
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2.5. APOE GENE/PROTEIN: REGULATION OF CEREBRAL VESSELS 
There is little direct evidence to link variation in APOE genotype and protein to CV.  The apoE4 
protein is associated with increased neurotoxicity (Crutcher, Clay et al. 1994; Marques, Tolar et 
al. 1996; Tolar, Marques et al. 1997; Michikawa and Yanagisawa 1998; Moulder, Narita et al. 
1999).  This neurotoxicity has been associated with an influx of Ca++ from the extracellular space 
related to the secondary Ca++ homeostasis pathway involving G-protein activation and is apoE 
dose dependent, with increased influx associated with increased apoE level (Veinbergs, Everson 
et al. 2002).  Further, the influx occurs at when less apoE4 is available and is greater when the 
apoE4 isoform is present in the extracellular space as opposed to the apoE3 isoform (Muller, 
Meske et al. 1998; Veinbergs, Everson et al. 2002).  The apoE4 associated influx of Ca++ is 
sustained and nonreversible (Muller, Meske et al. 1998).  Given that the contractile activity of 
vascular smooth muscle is regulated by cytosolic Ca++ concentration, the Ca++ influx associated 
with apoE, specifically the apoE4 isoform could lead to complications following SAH, such as 
CV.  d’Uscio et al., developed a mouse model of human atherosclerosis, specifically an apoE 
knockout mouse.  They found that lack of apoE is associated with increased impairment of 
endothelial function related to inactivation of nitric oxide (NO) by superoxide ions in smooth 
muscle cells of apoE knockout mice (d'Uscio, Baker et al. 2001).  These results have been 
supported by the work of others (d'Uscio, Smith et al. 2001; Brown, Wright et al. 2002).  Sacre 
and associates found that the presence apoE3 stimulates more NO release in cultured human 
endothelial cells than apoE2 or apoE4 (Sacre, Stannard et al. 2003).  Vascular relaxation is 
dependent upon NO and a decrease in NO associated with apoE2 or apoE4 could lead to 
ineffective vascular reactivity and CV.  Kay and associates (2003) found that in humans apoE 
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CSF concentration was lower after SAH when compared to that of controls (Kay, Petzold et al. 
2003) suggesting that apoE may be utilized at an increased rate after SAH.  
  
2.6. SIGNIFICANCE 
The premise of this study is that after SAH cytosolic Ca++ homeostasis shifts from primary to 
secondary pathways.  Exposure of the vessel walls to increased available apoE protein and Ca++ 
in the CSF, via SAH, results in an increase in apoE attachment to the receptors in the cells of the 
vessel wall.  This phenomenon can in turn lead to a G-protein linked increase in cytosolic Ca++ 
level, vascular smooth muscle cell contraction and hence vessel contractility (i.e. CV). 
Nurses, as the caregivers that monitor neurologic status of patients following SAH, 
identify changes indicative of hypoxia and ischemia caused by CV.  The ability to a priori 
identify subsets of individuals at greatest risk for CV and the associated poorer outcomes using 
genetic biomarkers would lead to better utilization of nursing resources in the form of increased 
monitoring of these patients.  It would also encourage the development apoE-Ca++ based 
treatment options tailored to an individuals genetic background aimed at increasing odds of 
survival and improving function of survivors.   
While APOE genotype has been implicated in many neurodegenerative disease processes 
and recovery from acute neurologic injury, it has not been thoroughly explored in the SAH 
population.  ApoE protein expression has rarely been considered, and isoform specific effects in 
relation to cytosolic Ca++ level and CV has not been investigated in this population.  Knowledge 
of how genetic differences impact recovery from SAH could advance our knowledge of the 
biology of secondary injury following SAH and aid in efforts at designing individualized 
treatment. 
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 3. PILOT STUDIES 
 
This series of pilot studies were conducted as a component of an independent study to acquire 
skill in measuring apoE protein level and Ca++ level in CSF.   The overall purpose of these 
studies was to pilot test the laboratory techniques involved in the measurement of these variables 
and to collect data for effects size calculations for the larger study.   
 
3.1. PRELIMINARY STUDY #1:  APOE GENOTYPE AND OUTCOME AFTER SAH 
3.1.1. Introduction 
Apolipoprotein E (APOE) genotype has been associated with outcomes after many neurologic 
injuries, most commonly with presence of the ε4 allele associated with poorer outcome after both 
severe TBI and stroke.  The association between APOE genotype and outcome after SAH is 
inconclusive with some researchers finding the APOE ε4 allele associated with poorer outcomes 
(Niskakangas 2001; Leung, Poon et al. 2002) while others did not find any significant 
association (Dunn, Stewart et al. 2001). 
3.1.2. Specific Aims 
The purpose of this project was to examine outcome after SAH in relation to APOE genotype. 
3.1.3. Methods 
This study used a nonequivalent two-group design to investigate the relationship between APOE 
genotype and outcome, as measured by the Glasgow Outcome Score (GOS) and mortality at 6 
months after injury, in patients recovering from an aneurysmal SAH.  Subjects for this study 
were taken from a larger population of individuals entered into a larger study after informed 
 29
consent was obtained.  Criteria for this study included 1) age 18-75, 2) admitted with a diagnosis 
of severe aneurysmal SAH (Fisher grade ≥2 or Hunt and Hess grade ≥3), 3) without previously 
existing static neurologic disease, 4) CSF available for genotyping and 5) 6 month GOS 
available.  Age and severity of injury measures (Fisher grade, Hunt and Hess grade, and Glasgow 
coma score) were extracted from the medical record prospectively as part of the parent study.  
CSF samples were drawn from an extraventricular drainage bag on the day of consent.  APOE 
genotype was assessed using standard restriction fragment length polymorphism analysis.  
Patients were classified by APOE ε4 allele presence (APOE4+) or APOE ε4 allele absence 
(APOE4-).  GOS and mortality were obtained by a trained researcher during telephone interview 
with the subject, their significant other, or physician office.  GOS was dichotomized into ‘good’ 
(GOS = 4 or 5) and ‘poor’ (GOS =1, 2, or 3).  Descriptive statistics, t-tests and Chi square 
analysis were conducted using SPSS v11.0.   
3.1.4. Results 
Forty-five subjects (mean age of 53.4 years) were recruited into the parent study, had complete 
outcome data at 6 months post-SAH and samples available for genotyping.  The sample was 
73.3% female, and 93.3% Caucasian.  Thirty-one (68.9%) patients had APOE genotype =3/3, 11 
(24.5%) patients had APOE 3/4 genotype, 2 (4.4%) patients had APOE 2/3 genotype and 1 
(2.2%) patient had APOE 2/4 genotype.  The sample was divided into two groups based on 
APOE ε4 allele presence, the APOE 4+ group (n=12; 26.7%) and the APOE 4- group (n=33; 
73.3%).   
Based on t-test analysis, there were no significant differences in age or admission 
Glasgow coma score.  Using Chi-square analysis, there were no significant differences in Fisher 
scores or race between the two groups.  A significant association was found between APOE ε4 
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allele presence and Hunt and Hess scores, with individuals with the APOE ε4 allele having a 
lower Hunt and Hess score (indicating less severe injury) (X2 = 11.29; p = 0.023).  Using Chi-
square analysis there were no significant differences in good versus poor outcome or mortality 
based on genotype.   
3.1.5. Conclusions 
While individuals with an APOE ε4 allele presented with less severe initial injuries, there was no 
significant difference in outcome. This suggests that individuals with the APOE ε4 allele have a 
response to the initial hemorrhage that is different from those without an APOE ε4 allele. 
 
3.2. PRELIMINARY STUDY #2:APOE PROTEIN LEVEL IN CSF AFTER SAH 
3.2.1. Introduction 
CV occurs when cerebral blood vessel diameter decreases causing decreased delivery of blood to 
brain tissue.  The contractility of vascular smooth muscle is regulated by cytosolic calcium 
(Ca++).  Following SAH, primary pathways of Ca++ homeostasis are disrupted and secondary 
pathways, such as the apolipoprotein E (apoE) pathway may play a greater role in regulating 
Ca++ influx.  The role of the apoE protein, a secondary Ca++ homeostasis pathway has never been 
examined in the development of CV after SAH. 
3.2.2. Purpose 
The purpose of this project was to 1) examine CSF apoE protein level over time in relation to CV 
status after SAH and 2) determine whether differences exist in apoE protein level over time in 
individuals with and without an APOE 4 allele. 
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3.2.3. Methods 
This study used a matched cohort design.  Individuals between the ages of 18-75 admitted with a 
diagnosis of severe aneurysmal SAH (Fisher grade >=2 or Hunt and Hess grade >=3) entered 
into a larger study after informed consent was obtained were considered for entry into this study.  
Only individuals who had cerebral angiography and an EVD (with CSF sampling) were 
considered for entry into this study.  Six patients with CV were matched on severity of 
hemorrhage, age, race and gender to 6 patients without CV (N=12).  Hunt and Hess and Fisher 
grades were matched within 1 level of categorical assignment.  Presence/absence of CV was 
verified by cerebral angiography.  Subjects were dichotomized into two groups based on CV 
status (CV+ versus CV-).  Daily CSF samples were drawn from day of consent to day 12 after 
SAH.  APOE genotype was assessed using standard restriction fragment length polymorphism 
analysis.  While subjects were not matched on genotype, they were dichotomized into two 
groups based on APOE ε4 allele presence (APOE4+ versus APOE4-).  ApoE protein levels were 
measured using enzyme linked immunoassay analysis.  Descriptive statistics, t-tests and graph 
analysis were conducted using SPSS v11.0.   
3.2.4. Results 
The overall mean total apoE protein level across all patients at all time points was .577 ng/ml 
(SD=.441).  Baseline apoE protein levels were .624 ng/ml (SD=.56) in patients with CV and .529 
ng/ml (SD=.33) in patients without CV (t=-.358; p=.09) (See figure 1).  Individuals without CV 
had a greater increase in apoE protein level over time as compared to those with CV (t=2.26; 
p=.047).   
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Figure 4.  Mean apoE level by sample day by CV 
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Figure 5.  Mean apoE level over time by APOE ε4 allele presence 
 
3.2.5. Conclusions 
Sustained lower apoE protein levels are associated with CV after SAH and APOE genotype may 
influence apoE protein level.     
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3.3. SUMMARY OF PRELIMINARY STUDIES 
These preliminary studies show that the PI has the ability to perform apoE protein quantification 
using ELISA methodology, and Ca++ level quantification using potentiometry.  Results of 
preliminary study #1 investigating outcome by APOE genotype, while not statistically 
significant, will provide data for sample size estimation for the proposed project.  Preliminary 
study #2 showed that not only are there differences in apoE protein level in groups based on 
presence/absence of CV, there are also differences based on genotype.  This pilot study shows 
that further exploration of this question is necessary to determine long-term effects of apoE on 
CV and outcome after SAH.  This preliminary work shows that it is feasible for this PI to carry 
out the larger proposed study.      
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 4. METHODS 
 
4.1. DESIGN 
This descriptive, prospective study used a between-group, within-subject design to examine daily 
apoE protein and Ca++ levels in CSF over time classified by presence of at least one copy of the 
APOE ε4 allele (APOE ε4 allele presence) in 97 individuals (with and without CV) admitted to 
University of Pittsburgh Medical Center. 
 
4.2. SAMPLE 
The population presenting to the University of Pittsburgh Medical Center for treatment of severe 
SAH is approximately 60% women and 9% African American, which is consistent with the 
general SAH population.  All patients admitted to the Neurovascular Intensive Care Unit were 
screened for eligibility based on the following criteria.    
Inclusion criteria: 
1.    21-75 years of age 
2. Diagnosis of subarachnoid hemorrhage (Hunt and Hess grade ≥3 or Fisher grade ≥2) verified 
by CT scan 
3.   Subsequent verification of a cerebral aneurysm as the probable cause of SAH 
4.   Placement of a CSF drainage catheter within 3 days of SAH 
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Exclusion criteria: 
1.  Any pre-existing, uncontrolled or nonstatic chronic neurologic disease or deficit  
2. SAH resulting from a traumatic injury, mycotic aneurysm, or arterio-venous malformation 
3. Died within 72 hours after hospital admission, precluding evaluation of CV. 
 
Children were not included in this study because the incidence of aneurysmal SAH in children is 
<.001% (Anderson, Jamrozik et al. 1993).  Patients with a diagnosis of subarachnoid hemorrhage 
graded as Hunt and Hess  ≥ 3 and Fisher grade ≥ 2 have an increased risk of CV.  Individuals 
with a pre-existing, static neurological condition were excluded to avoid confounding of the 
initial neurologic severity of injury assessment.  Patients with SAH from non-aneurysmal 
sources have a different course of recovery and a decreased risk of CV and were therefore 
omitted from this project. 
 
4.3. RATIONALE FOR SAMPLE SIZE 
The rationale for the sample size was based on previous recruitment/enrollment history and  
Power Analysis and Sample Size software [(PASS) NCCS Statistical Software, Kaysville, Utah] 
analysis.   In this population, the mean and variance of apoE protein levels are unknown, making 
effect size difficult to predict.  Using PASS analysis and a sample size determined to be feasible, 
the minimum effect size that could be detected for each specific aim is identified below. 
Given a sample size of 97 subjects: 
1.  Specific aim #1 would detect an effect size of 0.30 for differences in apoE protein expression 
in CSF of individuals with and without an APOE ε4 allele over the first 1-14 days after SAH at 
α=.05.   
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2.  Specific aim #2 would detect an effect size of 0.30 for differences in CSF Ca++ levels, in 
relation to APOE genotype of individuals with and without CV over the first 1-14 days after 
SAH at α=.05. 
3.  Specific aim #3 would detect an effect size of 0.20 for differences in CSF Ca++ levels 
and apoE protein expression in CSF of individuals with and without CV while controlling for 
APOE ε4 allele presence over the first 1-14 days after SAH at α=.05.     
Samples were collected from July, 2001 through November, 2003.  A total of 97 subjects 
were recruited and had daily specimens were available for analysis.   
 
4.4. SETTING 
Subjects were recruited from the Neurovascular Intensive Care Unit (NVICU), Presbyterian 
University Hospital, University of Pittsburgh Medical Center (UPMC), Pittsburgh Pennsylvania.  
This 10 bed unit is designed to care for individuals in the acute phase of neurologic injury. 
 
4.5. RECRUITMENT 
This project is linked to two prospective studies involving patients that experienced a SAH 
(NIH/NINR RO1 NR04339, PI- Dr. Kerr and Copeland Foundation Grant, PI- Dr. Kassam).  
Approximately 2 patients per month were recruited into the study.   Project personnel made daily 
rounds on the NVICU with the nursing staff.  Potential patients, with a diagnosis of SAH were 
reviewed for eligibility criteria.  Once eligibility was established, the bedside nurse reviewed the 
study briefly with the patient or the patients’ family and asked if study personnel could present 
the study to them.  If the patient/representative was willing, the nurse would introduce the study 
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personnel. Project personnel would present the study, and obtain informed consent.  Both studies 
were reviewed and approved by the University of Pittsburgh Institutional Review Board.  In 
order to assure subject confidentiality, all identifiers were removed from medical records and 
samples.   A nonidentifying study number was given to link the sample and medical record data. 
 
4.6. STANDARD MEDICAL CARE 
All individuals presenting to the UPMC PUH with SAH were admitted to the NVICU.  A CT 
scan of the head is done upon admission.  Hunt and Hess grade and Fisher grade were assigned 
by the neurosurgeon or a neuroradiologist upon admission.  Cerebral angiography was conducted 
to identify aneurysm and perform coiling and embolization of the aneurysm if that was the 
preferred treatment for the patient (as determined by attending neurosurgeon).  If coiling and 
embolization were not performed, surgical clipping of the aneurysm was conducted as soon as 
possible.  Continuous arterial blood pressure (ABP), central venous pressure (CVP), pulse 
oximetry, respiratory rate and cardiac rate and rhythm were monitored.  Extraventricular drain or 
lumbar drain was placed if necessary (for ICP maintenance) and ICP was monitored 
continuously.  Temperature was monitored rectally or orally every two hours.  Complete 
neurologic exam was conducted every 1 hour for the first 24 hours after admission and then 
every 2 hours until discharge from the NVICU.  Normovolemia was maintained with fluid bolus.  
Mean arterial blood pressure was maintained with anti-hypertensives or vasopressors.  The head 
of the bed was elevated 30 degrees.  Nimodipine (Nimotop) was given at a dose of 60mg every 4 
hours for fourteen days as tolerated.   Anti-convulsants were administered.  Sedatives were 
administered as needed for agitation.   
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4.7. DATA COLLECTION 
Demographic and medical condition information was recorded onto data collection sheets by 
project personnel.  Data collection sheets were electronically transmitted directly into an 
automated data entry and verification system (Teleform).  Data was stored in a locked office of 
the PI of one of the parent studies (Kerr).  Cerebrospinal fluid (CSF) samples were drawn at least 
once every day using the University of Pittsburgh Medical Center standard procedure for 
ventriculostomy or lumbar drain bag changes.   Specimens were drawn only while the drainage 
catheter was in place for routine medical care.  Upon bag exchange, CSF was sampled from the 
bag and aliquoted into three-1 ml tubes and placed into a -80°C freezer located on the 2nd floor 
lab at Victoria Building, School of Nursing, University of Pittsburgh.  All analysis of specimens 
for the proposed project was conducted by the principal investigator of this study in the 
laboratory under the supervision and guidance of Dr. Conley.  Equipment was available in Dr. 
Conley’s laboratory to perform: Deoxyribonucleic Acid (DNA) extraction and amplification 
(using polymerase chain reaction), electrophoresis, UV light visualization, quantitative Enzyme-
Linked Immunosorbent Assay (ELISA) and potentiometry. 
 
4.8. MEASUREMENT 
The study independent variable was the presence and severity of CV.  APOE ε4 allele presence 
was treated as an independent variable in analysis of specific aim #3 and as a covariate for 
analysis of specific aim #1, #2.  Dependent variables were the levels of apoE protein and Ca++ in 
the CSF.  Data on the severity of injury and demographic characteristics (age, gender, race) was 
collected for investigation as potential covariates.   
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4.8.1. Independent variable: cerebral vasospasm 
CV was determined in one of three ways: report or direct view of cerebral angiogram (CA), 
report or direct view of computed topographic angiogram (CTA) or elevated transcranial 
dopplers (TCD) with clinical neurologic deterioration (CND).   For CA and CTA’s, vasospasm 
in the anterior cerebral and anterior communicating, middle cerebral, internal carotid, posterior 
cerebral and posterior communicating, and vertebral and basilar arteries was classified by a 
neurosurgeon or neuroradiologist.  Cerebral vessels with 0-25% constriction were coded as ‘none 
to minimal vasospasm (CV-).  Segments of cerebral vessels with ≥ 26% constriction were coded 
as moderate to severe vasospasm (CV+).  If the absence of CV was documented in the radiology 
report, the subject was coded as none to minimal vasospasm (CV-).  If the presence of moderate 
or severe CV was documented in the radiology report, the CA or CTA, the subject was coded as 
positive for moderate to severe vasospasm (CV+).    
Transcranial Dopplers (TCDs) were obtained daily.  A middle cerebral artery systolic 
velocity greater than 200mmHg, a mean velocity greater than 120 mmHg and/or a Lindegaard 
ratio greater than 2.5 was considered elevated.  Clinical neurologic deterioration (CND), defined 
as a decrease of >2 points in GCS or the National Institutes of Health Stroke Scale or 
computerized neurological assessment sheet, or a deterioration in papillary or motor response, or 
a documented focal or global neurologic change by the bedside nurse.  Presence of elevated 
TCDs and CND was coded as CV; no elevation in TCDs or CND was coded as CV-.   
4.8.2. Independent variable: APOE genotyping 
APOE genotype was detected from the CSF samples using the following DNA extraction, 
amplification, digestion and genotyping procedures. 
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4.8.2.1. DNA extraction.  The CSF specimens were quick thawed in small batches.  
Deoxyribonucleic acid (DNA) was extracted from the CSF using the following procedure based 
on the QiaAmp directions (Qiagen, Valencia, CA).  Twenty-five µl of each CSF sample was 
mixed with 200µl of buffer AL and 20µl Proteinase K and vortexed for 15 seconds.  An 
additional 200µl of buffer AL was added and samples were incubated at 70° C for ten minutes 
and spun down via micro-centrifuge.  Two hundred and ten µl’s of ethanol (96-100%) was added 
to each sample before vortexing for 10 seconds to precipitate the DNA.  The sample was poured 
into a spin column and centrifuged at 6000xg for 1 minute before being transferred to a new 
tube.  A 500 µl of buffer AW was added and centrifuged at 6000xg for 1 minute.  Excess buffer 
was poured off, leaving the DNA in the bottom of the tube.  Five hundred µl of buffer AW was 
added and the sample was centrifuged at full speed for 1 minute.  Excess buffer was poured off 
and the sample was placed into a clean tube and centrifuged for 1-minute before 400 µl of buffer 
AE was added.  Samples were then incubated at 70° C for 10 minutes, then centrifuged at 
6000xg for 1 minute.  The pellet was then resuspended in 1X TE buffer and stored at 4°C.   
4.8.2.2. DNA amplification.   DNA was amplified using a polymerase chain reaction (PCR) 
procedure defined by QIAGEN for use with ‘Proofstart DNA Polymerase’ (Qiagen, Valencia, 
CA).  A stock solution of ‘mastermix’ was created containing: 50µl 0X Proofstart buffer, 2.5mM 
MgSO4,  15µl dNTP, 15µl forward primer with sequence:   5' - TAA GCT TGG CAC GGC TGT 
CCA AGG A -3', 15µl reverse primer with sequence:   5' - ACA GAA TTC GCC CCG GCC 
TGG TAC AC - 3', 15µl Proofstart DNA polymerase, and distilled water to a total volume of 
500µl.  Ten µl of the mastermix solution and 1µl of the extracted DNA solution (for each 
patient) was placed into a microtube for each sample.  Microtubes were placed into a thermal 
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cycler and heated to 95° C for 5 minutes to activate Proofstart DNA polymerase.  The thermal 
cycler was programmed to heat to 94° C for 1 minute (to break the bonds between the two DNA 
strands),  50-68° C for 1 minute (to allow annealing), 72° C for 1 minute per 1 kilobase (to allow 
the nucleotide bases to link to the primers and replicate the region of DNA between them), and 
repeat 45 times (to produce more copies).  The thermal cycler then returned to a temperature of 
4° C (to stop the reaction and store the samples).   
4.8.2.3. Restriction length fragment polymorphism digestion.  The DNA digestion (or 
‘cut’) for the APOE gene was based on polymorphism (Gioia, Vogt et al. 1998).  The following 
procedure was used: 15 µl of amplified DNA, 7.5 U (0.75 l) of the Hha I restriction enzyme 
(New England Biolabs, MA) and 2µl of 10X buffer was incubated for 1.5 hours at 37°C.  Seven 
and a half U was added to the mixture and digestion continued for 1.5 hours. At the end of the 
incubation, the reactions were terminated by the addition of EDTA and electrophoresis dyes (R-
stop buffer). 
4.8.2.4. Genotyping procedure.  A polyacrilamide gel was prepared and placed into an 
electrophoresis machine.  Ten µl of orange dye was added to each of five of the 19µl of digested 
DNA product (sample), and then loaded into the first five wells of the 6 well gel.  Ten µl of 
1000kb DNA ladder was added to the final well.  The electrophoresis machine was turned on and 
run at 100mv for 2 to 2 1/2 hours until the dye had run 3/4ths of the way down the gel.  The 
electrophoresis machine was disconnected from the power source and the gel removed from the 
machine.  The gel was soaked in a solution of 5µl Ethidium Bromide dye in 200 cc’s 1X TBE for 
20 minutes, rinsed and viewed under UV light.  A computer generated picture of the gel was 
recorded.  Two independent researchers reviewed the pictures and assigned an APOE genotype 
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based on appropriate banding.   Genotyping was repeated in 10% of the samples to assure 
reliability.  The genotype mismatch was not greater than 10%, so the entire process did not need 
to be rerun on all samples. 
4.8.3. Dependent variable: total apoE protein and apoE4 protein quantification 
One ml of each CSF sample (each patient days 1-14) was thawed at room temperature and 
analyzed in batch using enzyme-linked immunosorbent assay (ELISA) analysis (MBL 
International Corp., Watertown, MA).  The quantity of total apoE protein in subject samples was 
compared against the quantity of apoE in a known standard concentration.  The apoE standard 
was prepared by diluting 2400 nanograms (ng) of lyophilized human apoE with 0.1ml of distilled 
water.  From that standard, seven standards of apoE at concentrations of 240 mg/L, 120 mg/L, 60 
mg/L, 30 mg/L, 15 mg/L, 7.5 mg/L and 3.78 mg/L were created.  Subject CSF samples were 
prepared by adding 5 microliters (µl) of CSF and 245µl of a diluent solution that is a 1:4 
concentration of assay diluent taken from the kit and distilled water.  One hundred µl of this 
diluted sample and each of the standards was put into two adjacent wells of a ninety-six well 
plate coated with anti-Human Pan-ApoE antibody.  The plate was covered and incubated at 37°C 
for 60 minutes.  Wells were then washed 4 times in an autowasher with 25°C temperature 
solution of 1:9 concentration of wash concentrate (Phosphate buffer solution).  One hundred µl 
of a 1:100 concentration of apoE conjugate solution (peroxidase conjugated apoE monoclonal 
antibody) in a conjugate diluent solution consisting of 1:20 concentration of conjugate diluent2 
to conjugate diluent1 was added to each well.  The plate was again covered and incubated at 
37°C for 60 minutes before being washed.  One hundred µl of substrate reagent (TMB/H2O2) 
was added to each well and the plate was covered and incubated at 37°C for 30 minutes.  One 
hundred µl of the stop reagent (0.5mol/L H2SO4) was added to each well and the plate was 
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placed into the plate reader.  Absorbance was determined using a 450nm wavelength to measure 
substrate catalysis by transmitting light through the well and measuring the amount of absorption 
of that light (Crowther 1995).  The mean absorbance value of each well was calculated and 
means of the duplicate wells were averaged.   
For subjects with the APOE ε4 allele, a second ELISA was performed using the above 
methodology but with the following substitutions.  The quantity of apoE4 protein in subject 
samples was compared against the quantity of apoE4 in a known standard concentration. 
Standards for the apoE4 at concentrations of 120 mg/L, 60 mg/L, 30 mg/L, 15mg/L, 7.5 mg/L, 
3.78 mg/L, and 1.89 mg/L were created using the same methodology as above, but beginning 
with 1200 ng of lyophilized human apoE4 protein.  Subject CSF samples were prepared by 
adding 5 microliters (µl) of CSF and 245µl of a diluent solution that is a 1:4 concentration of 
assay diluent taken from the kit and distilled water.  One hundred µl of this diluted sample and 
each of the standards was put into two adjacent wells of a ninety-six well plate coated with anti- 
Human Pan-ApoE antibody.  The plate was covered and incubated at 37°C for 60 minutes.  
Wells were then washed 4 times in an autowasher with 25°C temperature solution of 1:9 
concentration of wash concentrate (Phosphate buffer solution).  One hundred µl of a 1:100 
concentration of apoE4 conjugate solution (peroxidase conjugated apoE4 monoclonal antibody) 
in a conjugate diluent solution consisting of 1:20 concentration of conjugate diluent2 to 
conjugate diluent1 was added to each well.  The plate was again covered and incubated at 37°C 
for 60 minutes before being washed.  One hundred µl of substrate reagent (TMB/H2O2) was 
added to each well and the plate was covered and incubated at 37°C for 30 minutes.  One 
hundred µl of the stop reagent (0.5mol/L H2SO4) was added to each well and the plate was 
placed into the plate reader.  Absorbance was determined using a 450nm wavelength to measure 
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substrate catalysis by transmitting light through the well and measuring the amount of absorption 
of that light (Crowther 1995).  The mean absorbance value of each well was calculated and 
means of the duplicate wells were averaged. 
4.8.4. Dependent variable: Ca++ quantification 
The level of total Ca++ was quantified from the daily sample of CSF using potentiometry.  
Potentiometry is a method that uses electrical potential to determine concentration.  CSF sample 
(0.25 ml) was mechanically inserted into a partial electrical circuit completing the circuit.  Given 
that all other components of the electrical circuit are known, the Ca++ level can be computed as: 
Ca++ = total potential (measured) - known potential. 
Ca++ level measured with potentiometry has a detection precision (or degree of variation) 
of .008-.01 and accuracy is 98-99% (Covington et al. 1989). 
4.8.5. Covariate: severity of injury 
Severity of SAH was determined using two indices: the Hunt and Hess grade and Fisher Scores.   
The Hunt and Hess grading system is based on clinical symptoms, with scores ranging from zero 
(0), indicating no clinical symptoms, to five (5), indicating a comatose state (Hunt 1983).  Oshiro 
et al. (1997) found the Hunt and Hess scale interrater reliability to be good with a kappa value of 
0.41 (p=.0005) (Oshiro, Walter et al. 1997).  Gruber et al. (1998) found higher Hunt and Hess 
scores to be correlated with infarct related to CV (Gruber, Ungersbock et al. 1998). 
The Fisher scoring system is a tool that measures severity of neurologic injury based on 
amount and distribution of blood on CT scan.  Fisher scores range from zero (0) indicating no 
blood noted on CT scan, to four (4) indicating intracerebral or intraventricular clot with diffuse 
or no blood in the subarachnoid space (Fisher, 1980).  Ogilvy and associates found Fisher grade 
to have excellent interrater reliability with kappa value of 0.9 (Ogilvy and Carter 1998). Higher 
 48
Fisher scores have been correlated with CV after SAH (Lasner and Raps 1997; McGirt, 
Mavropoulos et al. 2003). 
4.8.6. Covariate: demographic characteristics 
Demographic information (age, gender, and race) was collected from the medical record  
upon entry into the study. 
 
4.9. DATA MANAGEMENT 
Subjects were assigned a unique identification code upon admission to the parent studies.  Data 
were linked by a unique identification code.  Data were entered into SPSS package [SPSS Inc, 
Chicago, Ill.].  Demographic data and severity of injury were entered electronically.  CV status 
and APOE genotype were hand entered into SPSS databases and verified.  Demographic data, 
severity of injury, and APOE genotype databases were merged and apoE protein levels, apoE4 
protein levels, and Ca++ levels, were hand entered and verified. 
 
4.10. DATA ANALYSIS PLAN 
4.10.1. Preliminary data analysis 
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4.10.1.1. Accuracy.  Accuracy of the data was assessed by screening for missing or out of 
range data.  Frequency analyses were performed for all categorical data (gender, race, genotype, 
CV and APOE ε4 allele presence).   There were no missing categorical or descriptive data.  
Missing data on serial samples (apoE protein, apoE4 protein, and Ca level) were controlled for 
using hierarchical linear modeling for the analysis.   
4.10.1.2. Normality.   Normality was assessed by examining histograms, skewness and 
kurtosis of each variable by research question.  No gross non-normality was found in these 
variables except for race, which was controlled for as a covariate in analysis.   
4.10.2. Primary data analysis 
Descriptive analyses were described using frequencies, percentages for categorical variables, 
means standard deviations and ranges for continuous variables.  Group comparisons were 
conducted using t-tests for continuous variables and Chi-square analysis for categorical 
variables.  Protein (apoE and apoE4) levels and Ca++ levels were described using mean, range 
and standard deviation of the entire sample and by group based on the presence or absence of CV 
and presence or absence of at least one copy of the APOE ε4 allele.  The trajectory of protein 
(apoE and apoE4) and Ca++ levels were examined using hierarchical linear modeling (HLM) and 
results presented as t-ratio and p value.  Criteria for level of significance was set at p=.05, criteria 
for trends was p=.10. 
4.10.3. Analysis of specific aims 
Specific aim #1.  Describe the total and apoE4 isoform-specific CSF apoE protein 
expression, in relation to APOE genotype, of individuals with and without CV over time for 
the first 1-14 days after SAH. 
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RQ1.  Is there a difference in total and apoE4 isoform-specific protein expression, in relation to 
APOE4 genotype, in CSF 1-14 days after SAH in individuals with and without CV? 
 
Specific aim #1 was analyzed using HLM to compare daily CSF apoE level in patients with and 
without CV while controlling for APOE ε4 allele presence and covariates (i.e. race, age, severity 
of injury).  HLM analysis is an excellent technique to examine serial samples across time and 
between groups because it is not necessary for all subjects to have the same number of CSF 
specimens available for analysis.  HLM controls for inconsistencies in the number of repeat 
measures by creating individual regression lines for each subject and computing an average 
regression line for the entire sample or by group.  This analysis examined apoE levels over time 
using the within subject repeated measures component (sample day after injury) as the level 1 
predictor.  Level 2 is the between subject component based on APOE4 group status, CV group 
status, and potential covariates (Hunt and Hess score, Fisher score, age, and race).  This model 
estimated the intercept and slope and by group and tested whether the intercept and slope 
differed by group based on APOE and CV group status.   The variances for the intercept and 
slope were estimated and tested to determine whether there is substantial group variability 
around both the mean starting and mean rate of change over time.   
The same analysis was applied to compare the daily CSF apoE4 protein levels while 
controlling for CV and covariates in individuals in the APOE4+ group.   
 
Specific aim #2.  Compare CSF Ca++ levels, in relation to APOE genotype, of individuals 
with and without CV over time for the first 1-14 days after SAH. 
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RQ2. Is there a difference in Ca++ levels, in relation to APOE4 genotype, in the CSF 1-14 days 
after SAH in individuals with and without CV? 
 
Specific aim #2 was assessed using HLM analysis as described in detail under specific 
aim #1.  HLM was used to compare daily CSF Ca++ level in patients with and without CV while 
controlling for APOE ε4 allele presence and the influence of covariates (i.e. race, age, severity of 
injury).  This analysis examined Ca++ levels over time with the within subject repeated measures 
component (sample day after injury) as the level 1 predictor variable.  Level 2 is the between 
subject component based on APOE4 group status, CV group status, and potential covariates 
(Hunt and Hess score, Fisher score, age, and race).  This model estimated intercept and slope by 
group and tested whether the intercept and slope differ by group based on APOE4 and CV.   The 
variances for the intercept and slope were estimated and tested to determine whether there is 
substantial group variability around both the mean starting and mean rate of change over time.   
 
Specific aim #3.  Compare the relationship between Ca++ levels and apoE (genotype and 
protein) in CSF of acutely ill individuals with and without CV over time for the first 1-14 
days after SAH.   
 
RQ3.  Is there a difference in the relationship between total apoE versus apoE4 isoform-specific 
protein expression and Ca++ level in the CSF 1-14 days after SAH in individuals with and 
without CV after controlling for APOE genotype? 
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Specific aim #3 was assessed using HLM.  HLM was used to assess the relationship 
between daily CSF Ca++ and apoE protein levels while controlling for APOE ε4 allele presence, 
CV presence and the influence of covariates (i.e. age, severity of injury).  This analysis examined 
apoE protein level over time with both the within subject repeated measures component (sample 
day after injury) and Ca++ level as level 1 predictor variables.  The level 2 between subject 
component was based on APOE4 group status, CV group status, and potential covariates (Hunt 
and Hess score, Fisher score, age, and race).  This model estimated means for the initial value 
and slope and tested whether the intercept and slope are significantly between groups based on 
APOE4 and CV group status over time.   The variances for the intercept and slope were 
estimated and tested to determine whether there is substantial group variability around both the 
mean starting and mean rate of change over time.   
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 5. RESULTS 
 
5.1. SAMPLE DESCRIPTION 
The mean age of the sample of 97 subjects was 53.7 years old (range 18 to 75; SD±12.8).  The 
sample was primarily Caucasian (n=89; 91.8%) and female (n=65; 67.0%).  Refer to table 1 for 
sample description.  Severity of hemorrhage as measured by the Fisher grade ranged from 2-4 
with a mode of 3 (n=65; 67.0%) (See table 2): the Hunt and Hess score ranged from 1-5 with a 
mode of 2 (n=31; 31.0) (See table 3).   
 
 Percent N  
Range SD Mean  
 67.0 65 Gender (female) 
 91.8 89 Race (caucasian) 
18-75 12.8 53.7 Age 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.  Demographic characteristics of sample. 
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 Percent n Fisher (*Mode) 
0 0 0- No CT scan 
0 0 1- No blood detected on CT scan 
14.4 14 2- Diffuse or vertical layers of blood <1mm  
67.0 * 65 * 3- Localized clot &/or vertical layers of blood >1mm*
18.6 18 4- Intracerebral or intraventricular clot with diffuse
or no SAH 
Table 2.  Severity of injury characteristics of sample: Fisher grade. 
 
 
Percentn Hunt & Hess (*Mode) 
15.5 15 1- Asymptomatic, mild headache, nuchal
rigidity 
32.0 * 31 * 2- Mod-severe HA, nuchal rigidity 
27.8 27 3- Other than cranial nerve palsy, drowsy 
15.5 15 4- Stupor, moderate to severe hemiparesis,
decerebrate 
9.3 9 5- Deep coma 
 
 
 
 
 
 
 
Table 3.  Severity of injury characteristics of sample: Hunt and Hess grade. 
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5.2. VARIABLES 
5.2.1. Independent variable: APOE genotype 
Figure 6 provides the genotype distribution of this sample.  See table 4 for a comparison of 
genotype distribution in this population to other North American populations.  Twenty-four 
subjects (24.0%) had an APOE ε4 allele present (see figure 7).  There were no significant 
differences between individuals with and without an APOE ε4 allele in categories of race, age, 
gender or severity of hemorrhage (Hunt and Hess or Fisher grade).  See table 5 for comparison of 
demographic and severity of hemorrhage scores by the presence/absence of an APOE ε4 allele. 
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Figure 6.  APOE genotype distribution of the sample. 
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Figure 7.  APOE4 allele presence in the sample. 
 
Current study .12 .83 .05 SAH  
N=97 
Zannis et al. (1981).17 .72 .11 All 
N=61 
DeCarli et al. 
(1999) 
.15 .76 .09 All (male, twins) 
N=396 
Referenceε4ε3ε2Population 
 
Table 4.  APOE allele frequencies of different North American populations 
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.68.56 .59.27.45 p 
F=.169F=.34 F=.29F=1.22t=.77 Statistic 
3 
(69.9)
2/3 
(28.8/30)1) 
68.5 
(50)
93.2 
(68)
52.0 
(12.6) 
APOE 4- 
3 
(58.3)
2 
(41.7) 
62.5 
(15)
87.5 
(21)
54.3 
(12.9) 
APOE4+ 
Fisher 
mode 
(%)
HH  
mode 
(%) 
Gender 
% female 
(n)
Race  
% white 
(n)
Age 
Mean 
(SD) 
 
Table 5.  Demographic and severity of injury characteristics by APOE4 allele presence 
 
5.2.2. Independent variable: presence of CV 
The presence or absence of CV was determined utilizing three methods.  Twenty-eight (28.9%) 
subjects had CV status verified by a cerebral angiogram reviewed by a project physician; an 
additional twenty-nine subjects (29.9%) had documentation of a cerebral angiogram by medical 
record review.   Five (5.2%) subjects had CV status verified by a CTA reviewed by a project 
physician; an additional 9 (9.3%) subjects had documentation of a CTA by medical record 
review.   The presence of CV determined by an elevation in TCDs associated with clinical 
neurologic deterioration was used to determine CV status of 26 (25.7%) subjects.  See figure 8 
and table 6 for diagnostic breakdown.  Fifty-three (54.6%) subjects were categorized as CV+ 
(see figure 9).  There was not a statistically significant difference in source of identification of 
vasospasm by vasospasm presence (χ2=4.7; p=.33).  The number of hours from hemorrhage to 
CV identification ranged from 30 to 360, with a mean of 129.83 hours (SD±67.63).  There were 
no significant differences between individuals with and without CV in categories of race, age, 
gender, Hunt and Hess score or Fisher grade (see table 7).   
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Total 
sample 
N=97 
CTA  
n=14 
TCD and 
CND 
n=26 
Angiogram 
n=57 
Study MD 
n=28 
Medical 
record 
review 
n=29
Study MD
n=5 
Medical 
record 
review 
n=9  
 
Figure 8.  CV diagnosis 
 
 
 
MR review 
n  
(%) 
Project MD 
read 
n  
(%) 
MR  
review 
n  
(%) 
Project MD 
read 
n  
(%) 
28 
(28.9) 
14 
(14.4) 
14 
(14.4) 
Cerebral Angiogram 
29 
(29.9)
11 
(11.3)
18 
(18.6)
Elevated 
TCDs with 
CND 
n  
(%) 
CTA  
26 
(26.8)
9 
(9.3) 
5 
(5.2)
Total 
11 
(11.3)
7 
(7.2) 
1 
(1.0)
CV- 
15 
(15.5)
2 
(2.1) 
4  
(4.1)
CV+ 
Table 6.  CV diagnostic method by group. 
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Figure 9.  CV distribution of the sample 
 
 
  % n Mode % n Mode  
.92 .01  90.9 40  92.5 49 Caucasian 
.15 2.08 36.4 16 2 32.117 3 Hunt & Hess 
 
70.5 
 
 
 
3 
37 
n 
52.5 
M 
.53 .41 63.6 28  69.8 Female 
p F % n  %  
.09 2.97 31 3 64.234 Fisher 
.32 1.01 12.9 55.1  12.7 Age 
SD M  SD 
 
p 
 
t 
CV- CV+  
Table 7.  Demographic and severity of injury by CV group 
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5.2.3. APOE ε4 allele presence and CV 
Of the 24 subjects with an APOE ε4 allele, 54.2% (n=13) had CV compared to 54.8% (n=40) of 
the 73 subjects without an APOE ε4 allele.  There were three subjects without CV data, none of 
whom had an APOE ε4 allele.  See table 8 for CV and CV diagnostic method by APOE ε4 allele  
presence. There was not a significant association between CV presence and APOE ε4 allele 
presence (χ2=.003; p=.96). 
 
97 
33 
40 
 
11 
 
13 
 
 
CV 
n 
(%) 
     APOE4- 
10 
(13.7) 
3 
(4.1) 
4 
(5.5) 
14 
(19.2) 
9 
(12.3) 
CV+ 
     APOE4+ 
4 
(16.7) 
0 
(0) 
0 
(0) 
4 
(16.7) 
5 
(20.8) 
CV+ 
 
0 
(0) 
0 
(0) 
1 
(4.2) 
4 
(16.7) 
6 
(25.0) 
CV- 
 
MR 
review 
n  
(%) 
Project 
MD read
n  
(%) 
MR  
review 
n  
(%) 
Project 
MD read 
n  
(%) 
28 
(28.9) 
8 
(11.0) 
Cerebral Angiogram 
29 
(29.9) 
7 
(9.6) 
Elevated TCDs 
with CND 
n  
(%) 
CTA  
25 
(25.8) 
10 
(10.3) 
5 
(5.2) 
Total 
11 
(15.1) 
7 
(9.6) 
0 
(0) 
CV- 
Table 8.  CV and CV diagnostic method by APOE ε4 allele presence 
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5.2.4. Dependent variable: total apoE protein level 
There were 703 samples available over time for analysis in 97 subjects.  Individuals had between 
1 and 13 samples available for analysis with an average of 7.6 samples per subject (SD±3.49).  
The total apoE protein level of all samples at all timepoints was a mean of 10.06 mg/L (Range 0-
68.8, SD±8.14). See table 9 for daily mean total apoE protein levels.     
 
5.2.4.1. Total apoE protein level and APOE ε4 allele presence.  The total apoE protein 
level of all samples at all timepoints in the APOE4+ group was a mean of 11.7 mg/L (range 0.25-
42.93, SD±7.59) as compared to the APOE4- group mean of 9.5 mg/L (range 0-68.76, SD±8.26). 
The APOE4+ group had a significantly higher mean total apoE protein level (t=-3.168; p=.002).  
See table 9 for daily mean total apoE protein levels by APOE4 group.     
 day 
1 
day 
2 
day 
3 
day 
4 
day 
5 
day 
6 
day 
7 
day 
8 
day 
9 
day 
10 
day 
11 
day 
12 
day 
13 
day 
14 
n 5 16 19 20 20 19 17 15 14 13 11 9 8 4 
APOE4+ 
Mean apoE 
(SD) 
14.4 
(14.1) 
11.3 
(7.5) 
9.9 
(5.1) 
11.4 
(10.1)
8.7 
(4.2)
10.1 
(5.0)
11.7 
(6.7)
11.4 
(8.3)
12.1 
(5.2)
12.5 
(5.3)
17.4 
(8.7) 
16.5 
(8.7) 
13.4 
(8.8)
13.6 
(8.1)
n 24 47 56 62 63 52 45 40 36 30 26 23 15 6 
APOE4- 
Mean apoE 
(SD) 
9.9 
(8.2) 
8.3 
(6.2) 
9.4 
(7.8) 
9.5 
(8.2) 
9.1 
(9.0)
9.6 
(11.2)
7.9 
(5.8)
8.4 
(5.9)
10.1 
(6.2)
12.2 
(12.3)
11.7 
(7.8) 
12.7 
(6.2) 
9.0  
(6.0)
11.8 
(8.5)
N 29 63 75 82 83 71 62 55 50 43 37 32 23 10 
Mean apoE 
(SD) 
10.7 
(9.3) 
9.1 
(6.6) 
9.5 
(7.2) 
10.0 
(8.9) 
9.0 
(8.1)
9.7 
(9.9)
8.9 
(6.3)
9.2 
(6.7)
10.7 
(6.0)
12.3 
(10.7)
13.4 
(8.4) 
13.8 
(7.1) 
10.6 
(7.2)
12.5 
(7.9)
Table 9.  Mean total apoE protein level (in mg/L) by day by APOE ε4 allele presence. 
5.2.4.2. Total apoE protein level and CV.  The total apoE protein level of all samples at all 
timepoints in the CV+ group was a mean of 11.7 mg/L (range .01-58.69, SD±8.43) as compared 
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to the CV- group mean of 9.5 mg/L (range 0-68.76, SD±7.69).  There was no significant 
difference in the overall average ApoE protein level between these two groups (t= 1.008; p=.32).   
See table 10 for daily mean total apoE protein levels by CV group.     
 day 
1 
day  
2 
day 
3 
day 
4 
day 
5 
day 
6 
day 
7 
day 
8 
day 
9 
day 
10 
day 
11 
day 
12 
day 
13 
day 
14 
n 18 35 43 45 47 42 39 35 32 28 26 23 16 6 
CV+ 
Mean apoE   
(SD) 
10.6 
(9.9) 
8.3 
(5.2) 
8.9 
(7.7)
9.4 
(9.3)
8.4 
(8.4)
10.2 
(11.3)
9.0 
(5.3)
9.0 
(6.4)
9.9 
(5.3)
10.6 
(4.9) 
13.2 
(7.7) 
14.4 
(7.0) 
10.6 
(7.2)
13.4 
(7.4)
n 11 28 32 37 36 29 23 20 18 15 11 9 7 4 
CV- 
Mean apoE  
(SD) 
10.8 
(8.6) 
10.0 
(7.4) 
10.3 
(6.5)
10.6 
(8.5)
9.8 
(7.6)
9.1 
(7.5)
8.9 
(7.8)
9.6 
(7.3)
12.0 
(7.0)
15.4 
(16.0) 
13.9 
(10.3) 
12.2 
(7.5) 
10.5 
(7.8)
11.3 
(9.7)
N 29 63 75 82 83 71 62 55 50 43 37 32 23 10 
ApoE level 
(SD) 
10.7 
(9.3) 
9.1 
(6.6) 
9.5 
(7.2)
10.0 
(8.9)
9.0 
(8.1)
9.7 
(9.9)
8.9 
(6.3)
9.2 
(6.7)
10.7 
(6.0)
12.3 
(10.7) 
13.4 
(8.4) 
13.8 
(7.1) 
10.6 
(7.2)
12.5 
(7.9)
Table 10.  Mean total apoE protein level (in mg/L) by day by CV group. 
5.2.5. ApoE4 protein level 
The overall apoE4 protein level of all samples in the APOE ε4 allele present group was a mean 
of 8.5 mg/L (Range 6.0-23.8, SD±6.6).  On average, apoE4 protein accounted for 62% of the 
total apoE protein in CSF.  See table 11 for mean apoE4 protein by day.   
 day 
1 
day 
2 
day 
3 
day 
4 
day 
5 
day 
6 
day 
7 
day 
8 
day 
9 
day 
10 
day 
11 
day 
12 
day 
13 
day 
14 
N 4 15 16 18 19 17 15 13 13 11 8 8 6 4 
Mean apoE4 
(SD) 
9.2 
(7.5) 
6.8 
(4.8) 
5.5 
(3.4) 
5.2 
(3.6) 
5.0 
(3.7)
8.8 
(9.5)
8.5 
(9.4)
10.8 
(13.2)
8.8 
(9.2)
6.4 
(3.7)
7.8 
(4.1) 
8.3 
(5.5) 
16.3 
(12.8)
13.1 
(11.0)
Table 11.  Mean apoE4 protein level (in mg/L) by day. 
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5.2.5.1. ApoE4 level and CV.  The apoE4 protein level of all samples at all timepoints in the 
CV+ group was a mean of 8.6 mg/L (range 1.9-20.8, SD±5.8) as compared to the CV- group 
mean of 8.4 mg/L (range 6.0-23.8, SD±7.8).  There was no significant difference in the mean 
apoE4 protein level of all samples at all timepoints of the two groups (t=-6.83; p=.50).  See table 
12 for mean apoE4 protein level by day by CV group. 
 day 
1 
day 
2 
day 
3 
day 
4 
day 
5 
day 
6 
day 
7 
day 
8 
day 
9 
day 
10 
day 
11 
day 
12 
day 
13 
day 
14 
n 3 9 9 10 11 9 9 8 8 7 5 5 4 4 
CV+ 
Mean apoE4 
(SD) 
11.2 
(7.8) 
6.1 
(2.8) 
5.1 
(3.4) 
5.7 
(3.1) 
5.6 
(4.3)
6.2 
(4.6)
7.3 
(2.8)
7.4 
(5.1)
6.8 
(3.6)
6.2 
(2.6)
7.8 
(4.1) 
10.6 
(5.9) 
9.3  
(7.7)
15.3 
(12.3)
n 1 6 7 8 8 8 7 6 5 4 3 3 2 1 
CV- 
Mean apoE4 
(SD) 
32.3 
n/a 
7.8 
(7.1) 
5.9 
(3.5) 
4.5 
(4.1) 
4.1 
(2.5)
11.8 
(12.8)
12.5 
(13.8)
10.2 
(15.1)
12.0 
(14.5)
6.9 
(5.6)
7.7 
(5.1) 
4.6 
(12.7) 
4.6  
(3.8)
6.3  
n/a 
N 4 15 16 18 19 17 15 13 13 11 8 8 6 4 
Mean apoE4 
(SD) 
9.2 
(7.5) 
6.8 
(4.8) 
5.5 
(3.4) 
5.2 
(3.6) 
5.0 
(3.7)
8.8 
(9.5)
8.5 
(9.4)
10.8 
(13.2)
8.8 
(9.2)
6.4 
(3.7)
7.8 
(4.1) 
8.3 
(5.5) 
16.3 
(12.8)
13.1 
(11.0)
Table 12.  Mean apoE4 protein level (in mg/L) by day by CV group. 
5.2.6. Total apoE and apoE4 ratio by CV 
See table 13 for total apoE to apoE4 ratio by day by CV.   
 day 
1 
day 
2 
day 
3 
day 
4 
day 
5 
day 
6 
day 
7 
day 
8 
day 
9 
day 
10 
day 
11 
day 
12 
day 
13 
day 
14 
n 4 15 16 18 19 17 15 13 13 11 8 8 6 4 
ratio 
(SD) 
9.2 
(7.5) 
6.8 
(4.8) 
5.5 
(3.4) 
5.2 
(3.6) 
5.0 
(3.7)
8.8 
(9.5)
8.5 
(9.4)
10.8 
(13.2)
8.8 
(9.2)
6.4 
(3.7)
7.8 
(4.1) 
8.3 
(5.5) 
16.3 
(12.8)
13.1 
(11.0)
Table 13.  Total apoE to apoE4 ratio by day 
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 5.2.7. Dependent variable: Ca++ level 
The Ca++ level of all samples at all timepoints was a mean of 0.97 meq/L (Range 0.2-1.79, 
SD±.26).   
5.2.7.1. Ca++ level and APOE ε4 allele presence.  The Ca  level of all samples at all 
timepoints in subjects with an APOE ε4 allele present was a mean of .89 meq/L (range .2-1.68, 
SD±.23) as compared to those without an APOE ε4 allele with a mean of 1.00 meq/L (range .41-
1.79, SD±.26).  There was a significant difference in the mean Ca  level of all samples at all 
timepoints in subjects with and without an APOE ε4 allele present (t=4.78; p=.00).  See table 14 
for mean Ca  by day by APOE ε4 allele presence.
++
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 day 
1 
day  
2 
day  
3 
day 
4 
day 
5 
day 
6 
day 
7 
day 
8 
day 
9 
day 
10 
day 
11 
day 
12 
day 
13 
day 
14 
n 5 15 18 20 20 19 17 15 13 13 11 9 8 5 
APOE4+ 
Mean Ca++  
(SD) 
.80  
(.2) 
.79 
(.21) 
.84 
(.21) 
.90 
(.21)
.91 
(.26)
.97 
(.29)
1.03 
(.26)
.99 
(.23)
.86 
(.18)
.85 
(.28) 
.83 
(.19) 
.83 
(.15) 
.86 
(.18)
.90 
(.24)
n 23 46 57 61 61 51 44 40 36 29 25 21 15 5 
APOE4- 
Mean Ca++  
 (SD) 
1.04 
(.28) 
1.03 
(.29) 
.98 
(.28) 
1.01 
(.23)
.97 
(.24)
.96 
(.26)
.99 
(.28)
.99 
(.28)
.98 
(.25)
1.00 
(.23) 
1.02 
(.27) 
1.03 
(.25) 
1.02 
(.30)
.94 
(.32)
N 28 61 75 81 81 70 61 55 49 42 36 30 23 10 
Mean Ca++  
 (SD) 
1.00 
(.27) 
.98 
(.28) 
.95 
(.27) 
.97 
(.27)
.95 
(.25)
9.6 
(.28)
1.00 
(.27)
.99 
(.26)
.95 
(.24)
1.00 
(.23) 
.96 
(.26) 
.97 
(.24) 
.97 
(.27)
.92 
(.27)
Table 14.  Mean Ca++ level (in meq/L) by day by APOE ε4 allele presence. 
5.2.7.2. Ca++ level and CV.  The Ca  level of all samples at all timepoints in the CV+ group 
was a mean of .96 meq/L (range .29-1.79, SD±.26) as compared to the CV- group was a mean of 
.99 meq/L (range .2-1.75, SD±.26).  There were trends suggesting a possible difference in Ca
level of all samples at all timepoints in subjects with and without CV (t=1.66; p=.098).  See table 
15 for mean Ca  level by CV group. 
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 day 
1 
day  
2 
day 
3 
day 
4 
day 
5 
day 
6 
day 
7 
day 
8 
day 
9 
day 
10 
day 
11 
day 
12 
day 
13 
day 
14 
n 16 33 42 44 45 41 38 35 32 26 25 21 16 7 
CV+ 
Mean Ca++  
(SD) 
.88  
(.15) 
.92 
(.24) 
.93 
(.26)
.96 
(.24)
.96 
(.26)
.99 
(.28)
1.03 
(.30)
1.00 
(.29)
.93 
(.26)
.92 
(.24) 
.95 
(.27) 
.95 
(.24) 
.96 
(.30)
.97 
(.29)
n 12 28 33 37 36 29 23 20 17 16 11 9 7 3 
CV- 
Mean Ca++  
 (SD) 
1.17 
(.34) 
1.04 
(.33) 
.98 
(.28)
.99 
(.22)
.95 
(.24)
.93 
(.25)
.96 
(.23)
.97 
(.20)
.98 
(.19)
1.01 
(.22) 
.98 
(.28) 
1.00 
(.25) 
.98 
(.23)
.81 
(.22)
N 28 61 75 81 81 70 61 55 49 42 36 30 23 10 
Mean Ca++  
 (SD) 
1.00 
(.27) 
.98 
(.28) 
.95 
(.27)
.97 
(.23)
.95 
(.25)
9.6 
(.28)
1.00 
(.27)
.99 
(.26)
.95 
(.24)
.95 
(.24) 
.96 
(.26) 
.97 
(.24) 
.97 
(.27)
.92 
(.27)
Table 15.  Mean Ca++ level (in meq/L) by day by CV group. 
 
5.3. RESEARCH QUESTIONS 
5.3.1. Research question #1 
1.  Is there a difference in total apoE and apoE4 isoform-specific protein expression, in relation 
to APOE4 genotype, in CSF 1-14 days after SAH in individuals with and without CV? 
5.3.1.1. Total apoE level over time.  There were significant changes in total apoE protein 
level over time (t-ratio=.091; p=.003), total apoE protein levels started out lower than normal and 
continued to decrease over time until day 10 post-bleed when they rose only to drop again on day 
13 post-bleed.  See figure 10 for predicted mean total apoE protein level over time. 
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Sample day post bleed
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7.0
6.0
 
Figure 10.  Predicted mean total apoE protein level (in mg/L) over time. 
5.3.1.2. Total apoE level over time by APOE ε4 allele presence.  There were no significant 
differences in the daily total CSF apoE levels (t-ratio=1.30; p=.195) or in the trajectory of those 
levels in subjects with and without an APOE ε4 allele present (t-ratio=1.42; p=.157) (See figure 
11). See table 9 for mean total apoE protein level by day by APOE ε4 allele presence.   
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Sample day post bleed
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Figure 11.  Predicted mean total apoE protein level (in mg/L) by day by APOE ε4 allele presence. 
5.3.1.3. Total apoE level over time by CV presence.  There were no statistically significant 
differences in daily CSF total apoE protein level (t-ratio= -.08; p=.415) or trajectory of mean 
total apoE protein level by CV presence (t-ratio=.1.46; p=.143) (See figure 12). See table 10 for 
mean total apoE protein level by day by CV.   
Sample day over time
1413121110987654321
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l
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Figure 12.  Predicted mean total apoE protein level (in mg/L) by day by CV group. 
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5.3.1.4. Total apoE level by APOE ε4 allele presence and CV.  The total apoE protein level 
of all samples at all timepoints for subjects with an APOE ε4 allele and with CV (n=13) was a 
mean of 11.7 mg/L (range .25-42.9, SD±7.7 mg/L).   The total apoE protein level of all samples 
at all timepoints for subjects without an APOE ε4 allele and with CV (n=40) was a mean of 9.1 
mg/L (range .9-16.8, SD±3.4 mg/L).  The total apoE protein level of all samples at all timepoints 
for subjects with an APOE ε4 allele but without CV (n=11) was 11.6 mg/L (range .5-23.0, 
SD±5.7 mg/L).   The total apoE protein level of all samples at all timepoints for subjects without 
an APOE ε4 allele or CV (n=33) was 10.1 mg/L (range 0-68.7, SD±8.6 mg/L).  See figure 13 for 
graph of total apoE mean by subgroups. 
n=13 n=11 
 
Figure 13.  Mean total apoE protein level (in mg/L) by subgroups. 
5.3.1.5. Total apoE over time with covariates, APOE ε4 allele presence and CV.  There 
was not a significant association between daily CSF total apoE protein level and any covariates, 
APOE ε4 allele presence (t-ratio=.752; p=.452), or CV presence (t-ratio=-.705; p=.480).    
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5.3.1.6. Total apoE levels and apoE4 levels.  There was a significant association between 
mean total apoE protein level and mean apoE4 protein level (t-ratio=.526 p=.000), although this 
association did not change over time (t-ratio=.386, p=.702).  CV did not impact this relationship 
when added to the model (t-ratio=-.691; p=.497).  See table 16 for mean total apoE to apoE4 
ratio by day by CV.   
 day 
1 
day 
2 
day 
3 
day 
4 
day 
5 
day 
6 
day 
7 
day 
8 
day 
9 
day 
10 
day 
11 
day 
12 
day 
13 
day 
14 
n 1 6 7 6 8 6 4 2 3 3 2 1 1 1 
CV+ 
ratio 
(SD) 
.56 
n/a 
.56 
(.11) 
.47 
(.09) 
.41 
(.08) 
.51 
(.09)
.63 
(.08)
.62 
(.07)
.66 
(.07)
.54 
(.17)
.48 
(.08)
.48 
(.11) 
.39 
n/a 
.30  
n/a 
.44  
n/a 
n 3 7 7 8 9 7 8 6 7 6 4 5 4 2 
CV- 
ratio 
(SD) 
.61 
(.05) 
.56 
(.02) 
.63 
(.05) 
.53 
(.09) 
.63 
(.08)
.65 
(.07)
.65 
(.04)
.65 
(.04)
.55 
(.06)
.65 
(.10)
.65 
(.11) 
.68 
(.11) 
.74  
(.12)
.90  
(.01)
N 4 15 16 18 19 17 15 13 13 11 8 8 6 4 
ratio 
(SD) 
9.2 
(7.5) 
6.8 
(4.8) 
5.5 
(3.4) 
5.2 
(3.6) 
5.0 
(3.7)
8.8 
(9.5)
8.5 
(9.4)
10.8 
(13.2)
8.8 
(9.2)
6.4 
(3.7)
7.8 
(4.1) 
8.3 
(5.5) 
16.3 
(12.8)
13.1 
(11.0)
Table 16.  Total apoE to apoE4 ratio by day by CV 
5.3.1.7. ApoE4 levels over time by CV.  There was no statistically significant difference in 
daily mean apoE4 levels (t-ratio=1.16; p=.259) or trajectory of daily mean apoE4 protein levels 
by CV (t-ratio=1.412; p=.171).  See table 12 for mean apoE4 protein level by day by CV. 
5.3.2. Research question #2 
2. Is there a difference in Ca++ levels, in relation to APOE4 genotype, in the CSF 1-14 days after 
SAH in individuals with and without CV? 
5.3.2.1. Ca++ level over time.  Ca++ level did not change over time (t-ratio= -.549; p=.582).  
See figure 14 for modeled mean Ca++ level over time. 
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Figure 14.  Predicted mean Ca++ level (in meq/L) over time. 
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5.3.2.2. Ca++ level over time and APOE ε4 allele presence.  There was a significant 
difference in the daily Ca++ level of subjects with and without an APOE ε4 allele (t-ratio=-4.738; 
p=.000).  Individuals with an APOE ε4 allele had lower Ca++ levels, but there was not a 
difference in the trajectory across time (t-ratio=-0.265; p=.791). See figure 15 for graph of 
modeled Ca++ levels by APOE ε4 allele presence. See table 14 for mean Ca++ level by day by 
APOE ε4 allele presence.   
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Figure 15.  Predicted mean Ca++ level (in meq/L) by day by APOE ε4 allele presence. 
5.3.2.3. Ca++ level over time and CV.  There was no significant difference in daily Ca++ 
levels in subjects with and without CV (t-ratio=-.322, p=.740) nor was there a significant 
difference in the trajectory of Ca++ levels in subjects with and without CV (t=-.535; p=.592).   
See figure 16 for modeled Ca++ level by CV.  See table 15 for mean Ca++ level by day by CV 
group.   
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Figure 16.  Predicted mean Ca++ level (in meq/L) by day by CV group. 
5.3.2.4. Ca++ level and APOE ε4 allele presence and CV.  The Ca++ level of all samples at 
all timepoints for subjects with an APOE ε4 allele and CV (n=13) was a mean of .96 meq/L 
(range .29-1.68, SD± .24 meq/L). The Ca++ level in individuals without an APOE ε4 allele and 
with CV (n=40) was a mean of .96 meq/L (range .64-1.79, SD±.29 meq/L).   The Ca++ level of 
all samples at all timepoints for subjects with an APOE ε4 allele but without CV (n=11) was .78 
meq/L (range .2-1.14, SD±.21 meq/L).   The Ca++ level of all samples at all timepoints for 
subjects without an APOE ε4 allele or CV (n=33) was 1.05 meq/L (range .54-1.67, SD±.22 
meq/L).   See figure 17 for mean Ca++ level of subgroups.   
 
 74
00.2
0.4
0.6
0.8
1
1.2
AP
OE
4+
/C
V+
AP
OE
4+
/C
V-
AP
OE
4-/
CV
+
AP
OE
4-/
CV
-
APOE4+/CV+
APOE4+/CV-
APOE4-/CV+
APOE4-/
n=13 nn=40 =33
n=11
CV-
 
Figure 17.  Mean Ca++ level (in meq/L) by subgroups 
5.3.2.5. Ca++ level over time with covariates, APOE ε4 allele presence and CV.  There 
was a significant association between daily Ca++ level and APOE ε4 allele presence (t-ratio=-
4.738; p=.000).  Ca++ levels were lower in subjects with an APOE ε4 allele, but there were no 
differences in the trajectory across time between the two groups (t-ratio=-.265; p=.791).  There 
was no significant association between daily Ca++ level and CV presence (t-ratio=-1.576; 
p=.115). 
5.3.3. Research question #3 
3. Is there a difference in the relationship between total apoE and apoE4 isoform-specific protein 
expression and Ca++ level in the CSF 1-14 days after SAH in individuals with and without CV 
after controlling for APOE genotype? 
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5.3.3.1. Total apoE protein and Ca++ levels.  There was a statistically significant association 
between daily total apoE protein level and Ca++ level (t-ratio=3.458, p=.001), and this 
association did not change over time (t-ratio=-.098, p=.327).   
5.3.3.2. Total apoE protein and Ca++ levels and APOE ε4 allele presence.  When APOE 
ε4 allele presence was entered into the model, it was found to be a significant predictor (t-ratio=-
3.272, p=.001) however the association between daily total apoE protein level and daily mean 
Ca++ level remained essentially unchanged (t-ratio=3.586; p=.001).  Further, the fit of this model 
(indicated by a covariance component deviance of -328.54 vs –316.7) remained essentially 
unchanged.   
5.3.3.3. Total apoE protein and Ca++ levels and CV.  There was no significant change in 
the relationship between total apoE protein and Ca++ level in the presence or absence of CV (t-
ratio=-.217, p=.829).   
5.3.3.4. Total apoE protein and Ca++ levels, covariates, APOE ε4 allele presence and CV. 
The presence of the APOE ε4 allele was predictive (t-ratio=-3.272, p=.001) of the association 
between total apoE protein level and Ca++ level, with individuals without the APOE ε4 allele 
having a slightly stronger association. There were no changes in the model when covariates age 
(t-ratio=-.353, p=.724), race (t-ratio=.500, p=.616), gender (t-ratio=-1.282, p=.20), Hunt and 
Hess grade (t-ratio=.582, p=.56), Fisher grade (t-ratio=-.573, p=.566), or CV (t-ratio=-.204, 
p.838) were added  to the model. 
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5.3.3.5. ApoE4 protein and Ca++ levels.  There was no significant association between daily 
apoE4 protein and Ca++ levels (t-ratio=1.317, p=.201).   
5.3.3.6. ApoE4 protein and Ca++ levels and CV.  Controlling for the presence of CV, there 
was no change in the association between daily apoE4 protein and Ca++ levels (t-ratio=1.145, 
p=.264).   
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6. DISCUSSION 
 
This study examined the relationship between APOE genotype, daily CSF total apoE protein 
level, and daily CSF Ca++ levels in the presence and absence of CV after SAH.  We hypothesized 
that individuals with an APOE ε4 allele would have lower CSF Ca++ and total apoE protein 
levels and that individuals with CV would have lower CSF Ca++ and total apoE protein levels.   
 
6.1. APOE ε4 ALLELE PRESENCE 
Twenty-four percent of this population had an APOE ε4 allele as compared to approximately 30-
35% obtained in other studies of North American populations (Zannis 1986) (Decarli, Reed et al. 
1999).  While this difference was not significant, some suggest that the presence of the APOE ε4 
allele may predispose an individual to a more severe initial injury making survival to the hospital 
(and subsequent entry into study) less likely (McCarron and Nicoll 1998).  McCarron and Nicoll 
found that individuals with SAH had a higher than expected frequency of the APOE ε4 allele at 
autopsy (McCarron and Nicoll 1998).  Dunn and associates also found that the APOE ε4 allele 
was under represented in their SAH patient population (Dunn, Stewart et al. 2001).  Niskangas 
and associates found APOE ε4 allele representation of their SAH population similar to that of the 
general population in the area (Heilsinki) (Niskakangas 2001).  Tang and associates found a 
statistically insignificant higher representation of the APOE ε4 allele in their Chinese population 
as compared with controls (Tang, Zhao et al. 2003). 
  This study did not find APOE ε4 allele specific differences in admission severity of 
injury scores, however there were fewer individuals with an APOE ε4 allele than anticipated.  
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Other groups also found a lack of APOE ε4 allele specific differences in Hunt and Hess scores 
(Niskakangas 2001; Tang, Zhao et al. 2003) or Glasgow coma scores on admission (Dunn, 
Stewart et al. 2001).  Leung and associates found contrary results in that in their Chinese 
population, individuals with an APOE ε4 allele had higher World Federation neurologic scale 
scores, indicating worse clinical presentation on admission than individuals without an APOE ε4 
allele (Leung, Poon et al. 2002). Others did not collect clinical presentation measures on 
admission (Morris, Wilson et al. 2004).  This evidence suggests that in non-Asian populations, 
individuals with an APOE ε4 allele had similar or less severe clinical presentations on 
admission. 
   
6.2. APOE ε4 ALLELE PRESENCE AND CV 
This study found a relationship between APOE ε4 allele presence and Ca++ levels but no 
association between APOE ε4 allele presence and CV after SAH.  To our knowledge, this is the 
first study to examine APOE ε4 allele presence and possible mechanisms for CV.   
 While individuals with CV and with an APOE ε4 allele had the highest apoE levels, 
individuals without CV and without the APOE ε4 allele had the highest CSF Ca++ levels.  In the 
brain, the production and secretion of apoE by astrocytes increases in response to central nervous 
system injury (Messmer-Joudrier, Sagot et al. 1996; Lin, Duan et al. 1999; Duan, Gu et al. 2000).  
Intracellular Ca++ in both astrocytes and neurons increases in an apoE4 dose dependent manner, 
with apoE4 associated with greater levels of intracellular Ca++ (Muller, Meske et al. 1998).  The 
rise in Ca++ is associated with neurotoxicity and neuronal death (Tolar, Keller et al. 1999).  
Recent work of Ohkubo and associates suggests that the apoE induced increase in intracellular 
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Ca++ may trigger a further increase in Ca++ from other sources, including the endoplasmic 
reticulum but that these sources are not affected by the extracellular levels (Ohkubo, Mitsuda et 
al. 2001).  This may provide an explanation for the insignificant differences in daily Ca++ levels 
found in this study.  First, the initial apoE4-mediated increase in intracellular Ca++ triggers 
additional release of Ca++ from the endoplasmic reticulum in individuals with the APOE ε4 
allele.  The increase in CSF Ca++ in patients without the APOE ε4 allele may represent an 
increase in extracellular Ca++ from other sources independent of intracellular Ca++.  The shift of 
extracellular Ca++ into the intracellular space combined with a decrease in intracellular Ca++ 
clearance, increase vascular contraction contributing to CV.  The decrease in coupling we found 
between apoE protein and Ca++ level in APOE ε4 allele carriers suggests that as intracellular 
Ca++ is sequestered from other sources, the apoE- Ca++ association changes.      
       APOE ε4 allele carriers exhibit higher release of apoE protein after injury, and an 
increase in available extracellular apoE could translate to an increase in apoE binding to cell 
receptors causing an increased influx of Ca++ from extracellular to intracellular space (Veinbergs, 
Everson et al. 2002).  As expected, individuals with the APOE ε4 allele had an increase in apoE 
protein in the CSF.  We also found that individuals with the APOE ε4 allele had lower CSF Ca++ 
levels.  In that increased apoE from an extracellular source is known to increase cytosolic Ca++ 
and the apoE4 isoform also increases the influx of Ca++ from the extracellular space to the 
cytosol, these results suggest an isoform differential effect of Ca++ moving from the extracellular 
to intracellular space.  This may be seen as a lower CSF Ca++ levels.  It is also shown that 
increased intracellular Ca++ level may contribute to CV.  We found trends to support increased 
apoE and CV, but there was no increase CV seen in individuals with an APOE ε4 allele.  
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There are potential alternative mechanisms influencing vascular reactivity via an apoE 
mediated pathway.  L-arginine, which stimulates production of nitric oxide (NO), a potent 
vasodilator, has been shown to increase cerebral blood flow and decrease infarct volume in rats 
(Morikawa, Moskowitz et al. 1994).  Work by Colton and associates (Colton, Czapiga et al. 
2001) showed that apoE increases microglial and neuronal arginine uptake resulting in increased 
production of nitric oxide (NO).  Using a mouse model, they found that apoE4 presence was 
associated with a greater increase in cellular arginine uptake and NO production as compared to 
apoE3 mice or apoE deficient mice (apoE4>apoE3>apoE deficient) (Colton, Czapiga et al. 
2001).  Others have reproduced these findings.  Czapiga and Colton also found this relationship 
and that the apoE isoform specific increased arginine uptake and NO production is further 
enhanced in the presence of immune activation (Czapiga and Colton 2003).  NO mediated 
arterial relaxation is impaired in atherosclerosis (Zeiher, Drexler et al. 1991), a condition 
associated with presence of the APOE ε4 allele.  ApoE deficient mice have been found to have 
increased atherosclerosis and associated decreased NO-related endothelial relaxation.  An apoE-
mediated production of NO could account for decreased apoE in the CSF found in this study.  
The production of NO specifically requires Ca++ (Colton, Czapiga et al. 2001).  Reduced Ca++-
dependent NOS activity is an important component responsible for endothelial relaxation in 
blood vessels (d'Uscio, Baker et al. 2001).  If there were an increase in NO related to apoE 
induced cellular uptake, an associated decrease in extracellular Ca++, and hence CSF Ca++, as 
seen in the CV- group in this project would be anticipated.   
While this study did not examine long-term outcome, CV presence is associated with 
poorer long-term outcome (Weir 1995) and this study provides some clarification to the 
relationship between APOE ε4 allele presence and outcome after SAH.  Work by Tang (Tang, 
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Zhao et al. 2003), Leung (Leung, Poon et al. 2002), and Niskangas (Niskakangas 2001) found 
that presence of the APOE ε4 allele was associated with poor long term outcomes after SAH, but 
our work suggests that this does not occur as a result of CV.  Our work does provide some 
support for the work of Dunn and associates (Dunn, Stewart et al. 2001) who found that presence 
of the APOE ε4 allele was not associated with initial rebleed or outcome, good or poor, 6 months 
after SAH.  To some extent, this project also provides support for the work of Morris et al 
(Morris, Wilson et al. 2004) who considered APOE ε4 allele presence and broader long-term 
outcome measures including cognitive tests and global measures of function.  They found that 
while presence of the APOE ε4 allele was not directly associated with improved outcome after 
SAH, there were trends to indicate that individuals with at least one copy of the APOE ε4 allele 
and a more severe hemorrhage (i.e. Fisher=4) had better outcomes than their counterparts 
without an APOE ε4 allele (Morris, Wilson et al. 2004). 
   
6.3. TOTAL APOE PROTEIN LEVEL 
CSF total apoE protein levels were lower than normal [normal CSF total apoE protein level 
~20mg/L(Kay, Petzold et al. 2003)] after SAH, regardless of CV status, and continued to 
decrease over time until day 10.  Total apoE protein levels were higher in subjects with at least 
one copy of the APOE ε4 allele.  This finding agrees with the work of Kay et al. (2003) in that 
they also found CSF total apoE protein levels in the SAH population to be lower than normal 
(Kay, Petzold et al. 2003).  However, the mechanism for this finding is unclear.  The apoE 
protein may be utilized within the parenchyma as suggested by Kay, or within the cerebral 
vasculature as suggested by Paris and associates (Paris, Town et al. 1998).  While it is known 
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that apoE protein production is upregulated in the parenchyma after acute neurologic injury 
(Skene and Shooter 1983; Stoll and Muller 1986; Stoll, Meuller et al. 1989; Lin, Duan et al. 
1999; Duan, Gu et al. 2000) the increase in apoE production at the tissue level does not support 
the decrease noted in CSF.  One would speculate that apoE protein levels would be increased in 
the CSF after SAH due to the increase in apoE protein entering the CSF from plasma during the 
initial hemorrhage.  However, the decrease in total apoE level over time may also reflect 
increased uptake of apoE by neurons as they recover from this brain injury.  Other possible 
mechanisms for the decrease in CSF total apoE protein that occurs after SAH include an increase 
in apoE-bound lipoproteins (Gregg and Brewer 1986), very low density lipids (VLDL) and 
chylomicron bound apoE (Gregg and Brewer 1986) (Steinmetz, Jakobs et al. 1989), none of 
which would be detected by ELISA methodology used in this project.   
Kay also found that amyloid ß level was decreased in CSF after SAH, and that CSF total 
apoE protein and amyloid ß levels correlated.  Kay et al. suggested that when apoE protein 
interacts with other molecules, such as amyloid ß, the brain tissue indirectly sequesters more 
apoE protein from the CSF (Kay, Petzold et al. 2003).  Bound apoE, regardless of whether it is 
bound to lipids, a receptor, or some other molecule, would not be detected by ELISA 
methodology.  An increase in bound apoE could be responsible for the decrease in CSF apoE 
levels found by this study as well as that of Kay and associates. 
Alternatively, it is possible that apoE protein is utilized at a greater rate or that the protein 
itself is being broken down at an increased rate after injury.  It is known that apoE protein is 
produced by astrocytes and microglial after cerebral injury and incorporated into the neurons for 
use(Mahley, Huang et al. 1999; Sheng, Laskowitz et al. 1999; DeMattos, Brendza et al. 2001). 
While 60-80% of apoE protein internalized by hepatic cells is secreted for re-use (Swift, Farkas 
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et al. 2001), the potential for recycling of apoE in the central nervous system is not clear 
(Dekroon and Armati 2001).  It appears that this phenomenon occurs, although the mechanism 
differs for astrocytes and neurons and is also different for the different isoforms (Dekroon and 
Armati 2001).  This project was not designed to explore the utilization or break down of apoE 
protein.  Certainly, crossing of apoE protein from the CSF into the extracellular space and then 
into neurons for use is also an explanation for the finding of decreased levels in this study.   
The finding of lower apoE protein levels after SAH, indicate that apoE protein is either 
being broken down at rate higher than it is being produced, or it is being sequestered from the 
CSF for use in either the cerebral vasculature or brain tissue.  ApoE could be used in the cerebral 
vasculature to sequester Ca++ into the cell.  However, there were not significant differences in 
apoE protein level by CV group, indicating that these levels are not directly influencing CV 
presence.  Ca++ levels were not different based on CV group.  Interaction between apoE protein 
and Ca++ levels is evident from this project, however there was no significance based on CV 
group, indicating that there is some other mechanism influencing CV.  The apoE- Ca++ 
interaction could influence CV by increasing intracellular Ca++ levels while other mechanisms 
are also exerting influences.  For instance, if Ca++ is drawn into the cell via an apoE-mediated 
pathway, there could be additional influence on cerebral vascular response via another apoE 
pathway such as the NO pathway.  It is known that apoE can induce vascular relaxation by 
stimulating NO expression (Wang, Gruenstein et al. 1997; Colton, Needham et al. 2004).   
Alternatively, Paris and associates found apoE-induced vasoconstriction occurred in 
conjunction with beta-amyloid peptide, another common molecule that interacts with apoE in an 
isoform specific manner (E4>E3)(Paris, Town et al. 1998).  Binding of apoE with beta-amyloid 
could account for decreased level of apoE protein level in the CSF.   
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While this project provides valuable information about apoE isoforms, their presence in 
the CSF after SAH and apoE-Ca++ interaction, it did not find evidence to support this mechanism 
as the major influence on CV.  The additional hypotheses presented regarding apoE interactions 
with NO and beta-amyloid, while not supported by our data, are of sufficient interest to support 
further investigation.    
 
6.4. TOTAL APOE/APOE4 PROTEIN RATIO 
There was a significant association between total apoE protein level and apoE4 protein level.  
ApoE4 protein accounted for approximately 62% of the total apoE protein present in individuals 
with an APOE ε4 allele, and the total apoE protein level was higher in this group.  APOE 
genotype has not been associated with differences in CSF apoE levels (Kiunicki, Richardson et 
al. 1998).  The work of Kiunicki and associates did not measure isoform specific apoE protein 
but they did not find differences in total apoE protein level based on genotype (Kiunicki, 
Richardson et al. 1998).   
Of the 3 major apoE isoforms, apoE4 is cleared faster than the apoE2 or apoE3 from 
plasma (Gregg and Brewer 1986).  ApoE4 binds to the low density lipid receptor with equal 
affinity as apoE3, and binds to the low density lipid receptor related protein with equal affinity as 
apoE3 and apoE2.  However, apoE4 binds to VLDL with greater affinity (Dong and Weisgraber 
1996).  VLDL is cleared more rapidly from plasma and may be associated with apoE4 clearance 
as well (Gregg and Brewer 1986).   
ApoE is recycled in the liver, but the processing and potential recycling of different apoE 
isoforms is not as well defined in the CNS.  ApoE protein is processed and secreted for re-use by 
astrocytes more than neurons (Dekroon and Armati 2001).  This processing and release of apoE4 
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in higher amounts than apoE3 could account for apoE4 being more than half of the total apoE 
protein in CSF of this study.  If similar binding and clearance rates apply and the apoE is 
endocytosed back into the extracellular space, the slightly higher apoE4 in the CSF found by this 
project is not surprising.   
Possibly, the apoE4 protein is either not as likely to maintain the bond to the cellular 
receptor or is bound to lipids less often/for a shorter period of time.  The apoE4 protein is more 
susceptible to proteolysis (Brecht, Harris et al. 2004), so it is more likely that it would be broken 
down at an increased rate resulting in lower rather than higher levels.  ApoE3 protein may be 
bound at a higher percentage (due to affinity for select lipids and binding at cellular membrane) 
than apoE4 and would therefore not be detected using ELISA methodology, which measures free 
protein. 
It is possible that the APOE ε4 allele is in disequilibrium with a gene or promoter region 
that increases apoE protein production, however one would anticipate that only the apoE4 
isoform (being produced as a direct result of the chromosome with the APOE ε4 allele) would be 
elevated.  The finding that approximately 62% of total apoE protein is apoE 4 isoform supports 
this mechanism as having a role in this study.   
 
6.5. Ca++, TOTAL APOE PROTEIN AND APOE4 PROTEIN LEVELS 
Daily Ca++ and total apoE protein levels were correlated, however daily Ca++ and apoE4 protein 
levels were not correlated.  If apoE 4 protein is broken down at a higher rate than apoE 3 protein, 
as suggested by Brecht and associates (Brecht, Harris et al. 2004), there may be less apoE4 
protein available to stimulate uptake of intracellular Ca++.  An additional theory to explain this 
finding is related to sample size and the power to identify such an association.  ApoE4 protein is 
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only present in individuals with an APOE ε4 allele, therefore the sample size for analysis of the 
association between apoE4 protein and Ca++ levels is 24.  While there was not a significant 
association or a trend to indicate an association (p=.2), an increase in sample size may improve 
the association. 
   
6.6. Ca++ LEVELS 
Daily CSF Ca++ level was lower than normal (Normal CSF Ca++ level ~2.1 meq/L) after SAH.  
While Ca++ moves across the blood-brain barrier slowly (Tai, Smith et al. 1986), it can move 
freely between CSF and the extracellular space (Fenstermacher, Patlak et al. 1974) via the 
choroid plexus (Tai, Smith et al. 1986).  This free flow of Ca++ in conjunction with the findings 
of this study (low levels of CSF Ca++) suggest that the Ca++ exists either in a bound form in CSF, 
or a bound or unbound form in the CNS tissue or extracellular space.    
Individuals with CV had higher overall CSF Ca++ levels (all samples at all timepoints) 
than those without, but there was not a significant difference in the daily levels, suggesting a 
possible differential utilization of Ca++ in individuals with and without CV.  It is known that 
intracellular Ca++ of the cerebral blood vessels increases after SAH, and that this increase is more 
severe and prolonged with vasospastic vessels (Zuccarello, Boccaletti et al. 1996).  The higher 
concentration of CSF Ca++ levels of the CV+ group may be directly related to an increase in Ca++ 
availability to both neurons and cerebral blood vessels, contributing to vasospasm.   
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6.7. CONCLUSIONS 
The results of this study show that presence an APOE ε4 allele is not directly associated with 
CV, although there were trends to suggest differences in clinical presentation on admission.  
Total apoE protein levels were lower than normal after SAH, decreased for the first 10 days and 
then began to gradually increase.  Trends suggested that total apoE protein levels may be higher 
in individuals with an APOE ε4 allele; however there were no significant group differences in 
daily apoE protein levels across time.   Ca++ was linked to total apoE levels, and this relationship 
was strengthened in the presence of CV, suggesting that apoE may influence CV via Ca++ 
regulation.  There may be an allele differential role of apoE in intracellular Ca++ regulation.   
ApoE4 protein may encourage Ca++ uptake by cells and possibly increase vascular reactivity.  
Individuals with an APOE ε4 allele in the presence of CV had higher CSF Ca++ levels, 
suggesting that the increase in intracellular Ca++ level may be related to not only the initial surge 
of extracellular Ca++, but also to a potential secondary surge from the endoplasmic reticulum 
(Ohkubo, Mitsuda et al. 2001).  
  
6.8. IMPLICATIONS FOR FUTURE RESEARCH 
This study found a decreased incidence of the APOE ε4 allele in this SAH population.  Given the 
current literature, further work needs to be done to identify distribution of the APOE genotypes 
in this population and clarify the reasons for lower incidence of APOE ε4 allele frequency in 
some populations.   
While apoE protein level is implicated in vascular reactivity, there appear to be different 
mechanisms with different influences- i.e. via intracellular Ca++ regulation versus increased NO 
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production.  While this project was not specifically designed to determine the influence of 
different mechanisms on vascular reactivity, further work into the influence of these two 
contradictory mechanisms would make a valuable contribution.   
This project examined CSF Ca++ and apoE protein levels after SAH.  Future studies 
further examining the role of apoE and Ca++ at the cellular level are needed.  While some work 
has been done to identify the role of apoE in intracellular Ca++ maintenance, indicating that 
apoE4 isoform is linked with increase intracellular Ca++ uptake, the influence of this relationship 
on response to injury and disease is still not well defined.  Future work examining the linkage 
between apoE and Ca++ uptake into cells would be of value in determining influences on vascular 
reactivity as well as neurotoxicity. 
ApoE protein, and specifically the apoE4 isoform, induce neurotoxicity via Ca++  
homeostasis pathways.  While the apoE4 is associated with an increased Ca++ influx into the cell, 
there is still some ambiguity as to the source of this Ca++– extracellular versus intracellular and if 
intracellular from which organelle.    
 
 
 
 89
 
 
 
BIBLIOGRAPHY 
 
 
Alberts, B., D. Bray, et al. (1994). Molecular Biology of the Cell. New York, Garland 
Publishing, Inc. 
Anderson, C., K. Jamrozik, et al. (1993). “Predicting survival for 1 year among different 
subtypes of stroke. Results from the Perth Community Stroke Study. [see comments.].” 
Stroke 25(10): 1935-44. 
Barker, F. G., 2nd and C. S. Ogilvy (1996). “Efficacy of prophylactic nimodipine for delayed 
ischemic deficit after subarachnoid hemorrhage: a metaanalysis.” Journal of 
Neurosurgery 84(3): 405-415. 
Becker, K. G. (2001). “APOE genotype is a major predictor of long-term progression of 
disability in MS.” Neurology 57(11): 2148-9. 
Beffert, U., M. Danik, et al. (1998). “The neurobiology of apolipoproteins and their receptors in 
the CNS and Alzheimer's disease.” Brain Research - Brain Research Reviews 27(2): 119-
42. 
Bellosta, S., R. W. Mahley, et al. (1995). “Macrophage-specific expression of human 
apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null 
mice 
Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells 
produces differential effects on neurite outgrowth.” Journal of Clinical Investigation 
96(5): 2170-9. 
Brecht, W., F. Harris, et al. (2004). “Neuron-specific apolipoprotein e4 proteolysis is associated 
with increased tau phosphorylation in brains of transgenic mice.” Journal of 
Neuroscience 24(10): 2527-34. 
Brown, C. M., E. Wright, et al. (2002). “Apolipoprotein E isoform mediated regulation of nitric 
oxide release.” Free Radical Biology & Medicine 32(11): 1071-5. 
Chey, J., J. W. Kim, et al. (2000). “Effects of apolipoprotein E phenotypes on the 
neuropsychological functions of community-dwelling elderly individuals without 
dementia.” Neuroscience Letters 289(3): 230-4. 
Colton, C. A., M. Czapiga, et al. (2001). “Apolipoprotein E acts to increase nitric oxide 
production in macrophages by stimulating arginine transport.” Biochimica et Biophysica 
Acta 1535(2): 134-44. 
Colton, C. A., L. K. Needham, et al. (2004). “APOE genotype-specific differences in human and 
mouse macrophage nitric oxide production.” Journal of Neuroimmunology 147(1-2): 62-
7. 
Cook, D. A. (1995). “Mechanisms of cerebral vasospasm in subarachnoid haemorrhage.” 
Pharmacology & Therapeutics 66(2): 259-84. 
Crowther, J. R. (1995). “Elisa: Theory and practice.” Methods in Molecular Biology 42: 1-218. 
Crutcher, K. A., M. A. Clay, et al. (1994). “Neurite degeneration elicited by apolipoprotein E 
peptides.” Experimental Neurology 130(1): 120-6. 
 90
Czapiga, M. and C. Colton (2003). “Microglial function in human APOE3 and APOE4 
transgenic mice: altered arginine transport.” Journal of Neuroimmunology 134(1-2): 44-
51. 
Decarli, C., T. Reed, et al. (1999). “ Impact of apolipoprotein E epsilon4 and vascular disease on 
brain morphology in men from the NHLBI twin study.” Stroke 30(8): 1548-53. 
Dekroon, R. M. and P. J. Armati (2001). “Synthesis and processing of apolipoprotein E in human 
brain cultures.” GLIA 33(4): 298-305. 
DeMattos, R. B., R. P. Brendza, et al. (2001). “Purification and characterization of astrocyte-
secreted apolipoprotein E and J-containing lipoproteins from wild-type and human apoE 
transgenic mice.” Neurochemistry International 39(5-6): 415-25. 
DeMattos, R. B., L. K. Curtiss, et al. (1998). “A minimally lipidated form of cell-derived 
apolipoprotein E exhibits isoform-specific stimulation of neurite outgrowth in the 
absence of exogenous lipids or lipoproteins.” Journal of Biological Chemistry 273(7): 
4206-12. 
Dong, L. M. and K. H. Weisgraber (1996). “Human apolipoprotein E4 domain interaction. 
Arginine 61 and glutamic acid 255 interact to direct the preference for very low density 
lipoproteins.” Journal of Biological Chemistry 271(32): 19053-7. 
Dorsch, N. W. (1998). “The effect and management of delayed vasospasm after aneurysmal 
subarachnoid hemorrhage.” Neurologia Medico-Chirurgica 38 Suppl: 156-60. 
Dorsch, N. W. C. and M. T. King (1994). “A Review of Cerebral Vasospasm in Aneurysmal 
Subarachnoid Hemorrhage: Incidence and Effects.” Journal of Clinical Neuroscience 1: 
19-26. 
Duan, H., D. Gu, et al. (2000). “Sterols and inhibitors of sterol transport modulate the 
degradation and secretion of macrophage ApoE: requirement for the C-terminal domain.” 
Biochimica et Biophysica Acta 1484(2-3): 142-50. 
Dunn, L. T., E. Stewart, et al. (2001). “The influence of apolipoprotein E genotype on outcome 
after spontaneous subarachnoid hemorrhage: a preliminary study.” Neurosurgery 48(5): 
1006-10; discussion 1010-1. 
d'Uscio, L. V., T. A. Baker, et al. (2001). “Mechanism of endothelial dysfunction in 
apolipoprotein E-deficient mice.” Arteriosclerosis, Thrombosis & Vascular Biology 
21(6): 1017-22. 
d'Uscio, L. V., L. A. Smith, et al. (2001). “Hypercholesterolemia impairs endothelium-dependent 
relaxations in common carotid arteries of apolipoprotein e-deficient mice.” Stroke 
32(11): 2658-64. 
Fagan, A. M., G. Bu, et al. (1996). “Apolipoprotein E-containing high density lipoprotein 
promotes neurite outgrowth and is a ligand for the low density lipoprotein receptor-
related protein.” Journal of Biological Chemistry 271(47): 30121-5. 
Fenstermacher, J. D., C. S. Patlak, et al. (1974). “Transport of material between brain 
extracellular fluid, brain cells and blood.” Federation Proceedings 33(9): 2070-4. 
Fisher, C. M., J. P. Kistler, et al. (1980). “Relation of cerebral vasospasm to subarachnoid 
hemorrhage visualized by computerized tomographic scanning.” Neurosurgery 6(1): 1-9. 
Friedman, G., P. Froom, et al. (1999). “Apolipoprotein E-epsilon4 genotype predicts a poor 
outcome in survivors of traumatic brain injury.” Neurology 52(2): 244-8. 
Fujii, S. and K. Fujitsu (1988). “Experimental vasospasm in cultured arterial smooth-muscle 
cells.” Journal of Neurosurgery 69(1): 92-97. 
 91
Gioia, L., L. J. Vogt, et al. (1998). “PCR-based apolipoprotein E genotype analysis from archival 
fixed brain.” Journal of Neuroscience Methods 80(2): 209-214. 
Gregg, R. E. and H. B. Brewer, Jr. (1986). “In vivo metabolism of apolipoprotein E in humans.” 
Methods in Enzymology 129: 482-97. 
Gruber, A., K. Ungersbock, et al. (1998). “Evaluation of cerebral vasospasm after early surgical 
and endovascular treatment of ruptured intracranial aneurysms.” Neurosurgery 42(2): 
258-67. 
Hata, T., H. Kunugi, et al. (2002). “Possible effect of the APOE 4 allele on the hippocampal 
volume and asymmetry in schizophrenia.” American Journal of Medical Genetics 114(6): 
641-642. 
Hayashi, H., U. Igbavboa, et al. (2002). “Cholesterol is increased in the exofacial leaflet of 
synaptic plasma membranes of human apolipoprotein E4 knock-in mice.” NeuroReport 
13(4): 383-6. 
Holtzman, D. M., R. E. Pitas, et al. (1995). “Low density lipoprotein receptor-related protein 
mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-
derived neuronal cell line.” Proceedings of the National Academy of Sciences of the 
United States of America 92(21): 9480-4. 
Horsburgh, K., S. Kelly, et al. (1999). “Increased neuronal damage in apolipoprotein E-deficient 
mice following global ischaemia.” NeuroReport 10(4): 837-41. 
Hunt, W. E. (1983). “Clinical assessment of SAH.” Journal of Neurosurgery 59(3): 550-1. 
Ignatius, M. J., P. J. Gebicke-Harter, et al. (1986). “Expression of apolipoprotein E during nerve 
degeneration and regeneration.” Proceedings of the National Academy of Sciences of the 
United States of America 83(4): 1125-9. 
Jordan, B. D., N. R. Relkin, et al. (1997). “Apolipoprotein E epsilon4 associated with chronic 
traumatic brain injury in boxing.[comment].” JAMA 278(2): 136-140. 
Jordan, J., M. F. Galindo, et al. (1998). “Isoform-specific effect of apolipoprotein E on cell 
survival and Beta-amyloid-induced toxicity in rat hippocampal pyramidal neuronal 
cultures.” Journal of Neuroscience 18: 195-204. 
Kamboh, M. I., R. E. Ferrell, et al. (1998). “Genetic association studies between Alzheimer's 
disease and two polymorphisms in the low density lipoprotein receptor-related protein 
gene.” Neuroscience Letters 244(2): 65-8. 
Kandel, E. R. and J. H. Schwartz (1991). Principles of Neural Science. New York, McGraw-Hill. 
Kassell, N. F. (1985). “Cerebral vasospasm following aneurysmal subarachnoid hemorrhage. 
[see comments.].” STROKE 16: 562-72. 
Kassell, N. F. and J. C. Torner (1983). “Size of Intracranial Aneurysms.” Neurosurgery 12(3): 
291-297. 
Kay, A., A. Petzold, et al. (2003). “Alterations in cerebrospinal fluid apolipoprotein E and 
amyloid beta-protein after traumatic brain injury.” Journal of Neurotrauma 20(10): 943-
52. 
Kay, A. D., A. Petzold, et al. (2003). “Decreased Cerebrospinal Fluid Apolipoprotein E After 
Subarachnoid Hemorrhage: Correlation With Injury Severity and Clinical Outcome.” 
Stroke 34(3): 637-42. 
Kim, C. J., K. W. Kim, et al. (1999). “Role of Ca(2+)-dependent K+ channels in erythrocyte 
lysate-induced contraction of rabbit cerebral artery.” Neurological Research 21(7): 705-
11. 
 92
Kim, J. C., B. Wier, et al. (1996). “Hemolysate inhibits L-type Ca++ channels in rat basilar 
smooth muscle cells.” Journal of vascular research 33: 258-264. 
Kiunicki, S., J. T. Richardson, et al. (1998). “The effects of age, apolipoprotein E phenotype and 
gender on the concentration of amyloid- [small beta, Greek] (A [small beta, Greek] ) 40, 
A [small beta, Greek] 42, apolipoprotein E and transthyretin in human cerebrospinal 
fluid.” Clinical Biochemistry 31(5): 409-415. 
Kojima, M., S. Nagasawa, et al. (1998). “Asymptomatic familial cerebral aneurysms.” 
Neurosurgery 43(4): 776-81. 
Kutner, K. C., D. M. Erlanger, et al. (2000). “Lower cognitive performance of older football 
players possessing apolipoprotein E epsilon4.” Neurosurgery 47(3): 651-7; discussion 
657-8. 
LaDu, M. J., M. T. Falduto, et al. (1994). “Isoform-specific binding of apolipoprotein E to Beta-
amyloid.” Journal of Biological Chemistry 269: 23404-23406. 
LaDu, M. J., T. M. Pederson, et al. (1995). “Purification of apolipoprotein E attenuates isoform-
specific binding to beta-amyloid.” Journal of Biological Chemistry 270(16): 9039-42. 
Laskowitz, D. T., K. Horsburgh, et al. (1998). “Apolipoprotein E and the CNS response to 
injury.” Journal of Cerebral Blood Flow & Metabolism 18(5): 465-71. 
Laskowitz, D. T., H. Sheng, et al. (1997). “Apolipoprotein E-deficient mice have increased 
susceptibility to focal cerebral ischemia.” Journal of Cerebral Blood Flow & Metabolism 
17(7): 753-8. 
Lasner, T. M. and E. C. Raps (1997). “Clinical evaluation and management of aneurysmal 
subarachnoid hemorrhage.” Neuroimaging Clinics of North America 7(4): 669-78. 
Leung, C. H., W. S. Poon, et al. (2002). “Apolipoprotein e genotype and outcome in aneurysmal 
subarachnoid hemorrhage.” Stroke 33(2): 548-52. 
Lin, C., H. Duan, et al. (1999). “Apolipoprotein E-dependent cholesterol efflux from 
macrophages: kinetic study and divergent mechanisms for endogenous versus exogenous 
apolipoprotein E.” Journal of Lipid Research 40(9): 1618-1627. 
Ma, J., H. B. Brewer, Jr., et al. (1996). “Alzheimer A beta neurotoxicity: promotion by 
antichymotrypsin, ApoE4; inhibition by A beta-related peptides.” Neurobiology of Aging 
17(5): 773-80. 
Macdonald, R. L. (1991). “A review of hemoglobin and the pathogenesis of cerebral vasospasm. 
[see comments.].” Stroke 22(8): 971-82. 
Macdonald, R. L., B. K. A. Weir, et al. (1991). “Etiology of cerebral vasospasm in primates.” 
Journal of Neurosurgery 75(3): 415-424. 
Mahley, R. W. (1988). “Apolipoprotein E: cholesterol transport protein with expanding role in 
cell biology.” Science 240(4852): 622-30. 
Mahley, R. W., Y. Huang, et al. (1999). “Pathogenesis of type III hyperlipoproteinemia 
(dysbetalipoproteinemia). Questions, quandaries, and paradoxes.” Journal of Lipid 
Research 40(11): 1933-49. 
Mahley, R. W., B. P. Nathan, et al. (1996). “Apolipoprotein E. Structure, function, and possible 
roles in Alzheimer's disease.” Annals of the New York Academy of Sciences 777: 139-
45. 
Marques, M. A., M. Tolar, et al. (1996). “A thrombin cleavage fragment of apolipoprotein E 
exhibits isoform-specific neurotoxicity.” NeuroReport 7(15-17): 2529-32. 
Martorell, L., C. Virgos, et al. (2001). “Schizophrenic women with the APOE epsilon 4 allele 
have a worse prognosis than those without it.” Molecular Psychiatry 6(3): 307-10. 
 93
Mayberg, M. R., H. H. Batjer, et al. (1994). “Guidelines for the management of aneurysmal 
subarachnoid hemorrhage. A statement for healthcare professionals from a special 
writing group of the Stroke Council, American Heart Association.” Stroke 25(11): 2315-
28. 
McCarron, M. O., K. W. Muir, et al. (2000). “Prospective study of apolipoprotein E genotype 
and functional outcome following ischemic stroke.”  Archives of Neurology 57(10): 
1480-4. 
McCarron, M. O. and J. A. Nicoll (1998). “High frequency of apolipoprotein E epsilon 2 allele is 
specific for patients with cerebral amyloid angiopathy-related haemorrhage.” 
Neuroscience Letters 247(1): 45-8. 
McGirt, M., J. Mavropoulos, et al. (2003). “Leukocytosis as an independent risk factor for 
cerebral vasospasm following aneurysmal subarachnoid hemorrhage.” Journal of 
Neurosurgery 98(6): 1222-6. 
Messmer-Joudrier, S., Y. Sagot, et al. (1996). “Injury-induced synthesis and release of 
apolipoprotein E and clusterin from rat neural cells.” European Journal of Neuroscience 
8(12): 2652-61. 
Michikawa, M. and K. Yanagisawa (1998). “Apolipoprotein E4 induces neuronal cell death 
under conditions of suppressed de novo cholesterol synthesis.” Journal of Neuroscience 
Research 54(1): 58-67. 
Miyata, M. and J. D. Smith (1996). “Apolipoprotein E allele-specific antioxidant activity and 
effects on cytotoxicity by oxidative insults and beta-amyloid peptides.” Nature Genetics 
14: 55-61. 
Montine, K. S., S. J. Olson, et al. (1999). “Cerebral amyloid angiopathy-related hemorrhage. 
Interaction of APOE epsilon2 with putative clinical risk factors.” Experimental 
Neurology 158(1): 234-41. 
Morikawa, E., M. A. Moskowitz, et al. (1994). “L-arginine infusion promotes nitric oxide-
dependent vasodilation, increases regional cerebral blood flow, and reduces infarction 
volume in the rat.” Stroke 25(2): 429-35. 
Morris, P. G., J. Wilson, et al. (2004). “Apolipoprotein E polymorphism and neuropsychological 
outcome following subarachnoid haemorrhage.”  Acta Neurologica Scandinavica. 
Supplementum 109(3): 205-9. 
Moulder, K. L., M. Narita, et al. (1999). “Analysis of a novel mechanism of neuronal toxicity 
produced by an apolipoprotein E-derived peptide.” Journal of Neurochemistry 72(3): 
1069-80. 
Muller, W., V. Meske, et al. (1998). “Apolipoprotein E isoforms increase intracellular Ca2+ 
differentially through a omega-agatoxin IVa-sensitive Ca2+-channel.” Brain Pathology 
8(4): 641-53. 
Namba, Y., M. Tomonaga, et al. (1991). “Apolipoprotein E immunoreactivity in cerebral 
amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque 
amyloid in Creutzfeldt-Jakob disease.” Brain Research 541(1): 163-6. 
Nathan, B. P., S. Bellosta, et al. (1994). “Differential effects of apolipoproteins E3 and E4 on 
neuronal growth in vitro.” Science 264(5160): 850-2. 
Nathan, B. P., Y. Jiang, et al. (2002). “Apolipoprotein E4 inhibits, and apolipoprotein E3 
promotes neurite outgrowth in cultured adult mouse cortical neurons through the low-
density lipoprotein receptor-related protein.” Brain Research 928(1-2): 96-105. 
 94
Newell, D. W., M. S. Grady, et al. (1990). “Distribution of angiographic vasospasm after 
subarachnoid hemorrhage: implications for diagnosis by transcranial Doppler 
ultrasonography.” Neurosurgery 27(4): 574-7. 
Nicoll, J. A. and M. O. McCarron (2001). “APOE gene polymorphism as a risk factor for 
cerebral amyloid angiopathy-related hemorrhage.” Amyloid 8 Suppl 1: 51-5. 
Niskakangas, T. (2001). “Association of apolipoprotein E polymorphism with outcome after 
aneurysmal subarachnoid hemorrhage: a preliminary study. [see comments.].” Stroke 
32(5): 1181-4. 
Ogilvy, C. S. and B. S. Carter (1998). “ A proposed comprehensive grading system to predict 
outcome for surgical management of intracranial aneurysms.” Neurosurgery 42(5): 9959-
968. 
Ohkubo, N., N. Mitsuda, et al. (2001). “Apolipoprotein E4 stimulates cAMP response element-
binding protein transcriptional activity through the extracellular signal-regulated kinase 
pathway.” Journal of Biological Chemistry 276(5): 3046-53. 
Ohman, J. (1991). “Risks factors for cerebral infarction in good-grade patients after aneurysmal 
subarachnoid hemorrhage and surgery: a prospective study. [see comments.].” Journal of 
Neurosurgery 74: 14-20. 
Oshiro, E. M., K. A. Walter, et al. (1997). “A new subarachnoid hemorrhage grading system 
based on the Glasgow Coma Scale: a comparison with the Hunt and Hess and World 
Federation of Neurological Surgeons Scales in a clinical series.” Neurosurgery 41(1): 
140-7; discussion 147-8. 
Paris, D., T. Town, et al. (1998). “Isoform-specific vasoconstriction induced by apolipoprotein E 
and modulation of this effect by Alzheimer's beta-amyloid peptide.” Neuroscience Letters 
256(2): 73-6. 
Pepe, M. G. and L. K. Curtiss (1986). “Apolipoprotein E is a biologically active constituent of 
the normal immunoregulatory lipoprotein, LDL-In.” Journal of Immunology 136(10): 
3716-23. 
Peters, D. G., A. Kassam, et al. (1999). “Functional polymorphism in the matrix 
metalloproteinase-9 promoter as a potential risk factor for intracranial aneurysm.” Stroke 
30(12): 2612-2616. 
Peters, D. G., A. B. Kassam, et al. (2001). “Molecular anatomy of an intracranial aneurysm: 
coordinated expression of genes involved in wound healing and tissue remodeling.” 
Stroke 32(4): 1036-42. 
Poirier, J., A. Baccichet, et al. (1993). “Cholesterol synthesis and lipoprotein reuptake during 
synaptic remodelling in hippocampus in adult rats.” Neuroscience 55: 81-90. 
Poirier, J., M. Hess, et al. (1991). “Astrocytic apolipoprotein E mRNA and GFAP mRNA in 
hippocampus after entorhinal cortex lesioning.” Brain Research. Molecular Brain 
Research 11(2): 97-106. 
Pyne, G. J., T. A. Cadoux-Hudson, et al. (2001). “Cerebrospinal fluid from subarachnoid 
haemorrhage patients causes excessive oxidative metabolism compared to vascular 
smooth muscle force generation.” Acta Neurochirurgica 143(1): 59-62; discussion 62-3. 
Reyland, M. E., J. T. Gwynne, et al. (1991). “Expression of the human apolipoprotein E gene 
suppresses steroidogenesis in mouse Y1 adrenal cells.” Proceedings of the National 
Academy of Sciences of the United States of America 88(6): 2375-9. 
Ronkainen, A. (1999). “Familial subarachnoid hemorrhage in east Finland, 1977-1990. [see 
comments.].” STROKE 30(5): 1099-102. 
 95
Sacre, S. M., A. K. Stannard, et al. (2003). “Apolipoporotein E isoforms differentially induce 
Nitric Oxide production i n endothelial cells/.” FEBS Letters 540(1-3): 181-7. 
Saito, I., Y. Ueda, et al. (1977). “Significance of vasospasm in the treatment of ruptured 
intracranial aneurysms.” Journal of Neurosurgery 47(3): 412-29. 
Saunders, A. M., M. A. Pericak-Vance, et al. (1995). “Apolipoprotein E, survival in Alzheimer's 
disease patients, and the competing risks of death and Alzheimer's disease.” Archives of 
Neurology 52(7): 650-1. 
Schievink, W. I. (1997). “Genetics of intracranial aneurysms.” Neurosurgery 40(4): 651-62; 
discussion 662-3. 
Schievink, W. I. (1998). “Genetics and aneurysm formation.” Neurosurgery Clinics of North 
America 9(3): 485-95. 
Sheng, H., D. T. Laskowitz, et al. (1998). “Apolipoprotein E isoform-specific differences in 
outcome from focal ischemia in transgenic mice.” Journal of Cerebral Blood Flow & 
Metabolism 18(4): 361-6. 
Sheng, H., D. T. Laskowitz, et al. (1999). “Apolipoprotein E deficiency worsens outcome from 
global cerebral ischemia in the mouse.” Stroke 30(5): 1118-24. 
Skene, J. H. and E. M. Shooter (1983). “Denervated sheath cells secrete a new protein after nerve 
injury.” Proceedings of the National Academy of Sciences of the United States of 
America. 80(13): 4169-73. 
Solenski, N. J. (1995). “Medical complications of aneurysmal subarachnoid hemorrhage: a report 
of the multicenter, cooperative aneurysm study. Participants of the Multicenter 
Cooperative Aneurysm Study. [see comments.].” Critical Care Medicine 23(6): 1007-
1017. 
Steinmetz, A., C. Jakobs, et al. (1989). “Differential distribution of apolipoprotein E isoforms in 
human plasma lipoproteins.” Arteriosclerosis 9(3): 405-11. 
Stoll, G., H. W. Meuller, et al. (1989). “Oligodendrocytes but not astrocytes express 
apolipoprotein E after injury of rat optic nerve.” GLIA 2(3): 170-6. 
Stoll, G. and H. W. Muller (1986). “Macrophages in the peripheral nervous system and astroglia 
in the central nervous system of rat commonly express apolipoprotein E during 
development but differ in their response to injury.” Neuroscience Letters 72(3): 233-8. 
Strittmatter, W. J., D. Schmechel, et al. (1993). “Cholesterol synthesis and lipoprotein reuptake 
during synaptic remodelling in hippocampus in adult rats.” Neurology 43(8): 1467-72. 
Sun, Y., S. Wu, et al. (1998). “Glial fibrillary acidic protein-apolipoprotein E (apoE) transgenic 
mice: astrocyte-specific expression and differing biological effects of astrocyte-secreted 
apoE3 and apoE4 lipoproteins.” Journal of Neuroscience 18(9): 3261-72. 
Swift, L. L., M. H. Farkas, et al. (2001). “A recycling pathway for resecretion of internalized 
apolipoprotein E in liver cells.” Trends in Neurosciences 24(7): 392-400. 
Tai, C., Q. Smith, et al. (1986). “Calcium influxes into brain and cerebrospinal fluid are linearly 
related to plasma ionized calcium concentration.” Brain Research 385(2): 227-236. 
Tang, J., J. Zhao, et al. (2003). “Apolipoprotein E epsilon4 and the risk of unfavorable outcome 
after aneurysmal subarachnoid hemorrhage.” Surgical Neurology 60(5): 96-97. 
Teter, B., P. T. Xu, et al. (1999). “Human apolipoprotein E isoform-specific differences in 
neuronal sprouting in organotypic hippocampal culture.” Journal of Neurochemistry 
73(6): 2613-6. 
 96
Tolar, M., J. Keller, et al. (1999). “Truncated apolipoprotein E (ApoE) causes increased 
intracellular calcium and may mediate ApoE neurotoxicity.” Journal of Neuroscience 
19(16): 7100-7110. 
Tolar, M., M. A. Marques, et al. (1997). “Neurotoxicity if the 22kDa thrombin cleavage 
fragment of apolipoprotein E and related synthetic peptides is receptor-mediated.” 
Journal of Neuroscience 17: 5678-5686. 
Utermann, G., I. Kindermann, et al. (1984). “Apolipoprotein E phenotypes and hyperlipidemia.” 
Human Genetics 65(3): 232-6. 
van Gijn, J. and G. J. Rinkel (2001). “Subarachnoid hemorrhage: diagnosis, causes and 
management.” Brain 124(2): 249-278. 
Veinbergs, I., A. Everson, et al. (2002). “Neurotoxic effects of apolipoprotein E4 are mediated 
via dysregulation of calcium homeostasis.” Journal of Neuroscience Research 67(3): 379-
87. 
Vollrath, B., B. Weir, et al. (1990). “Hemoglobin causes release of inositol trisphosphate from 
vascular smooth muscle.” Biochemical & Biophysical Research Communications 171(1): 
506-11. 
Wang, J., S. Ohta, et al. (1994). “Changes in Ca(++)-ATPase activity in smooth-muscle cell 
membranes of the canine basilar artery with experimental subarachnoid hemorrhage.” 
Journal of Neurosurgery 80(2): 269-75. 
Wang, X. S., E. Gruenstein, et al. (1997). “Rapid elevation of neuronal cytoplasmic calcium by 
apolipoprotein E peptide 
Apolipoprotein E2 transgenic rabbits. Modulation of teh type III hyperlipoproteinemic 
phenotype by estrogen and occurrence of spontaneous atherosclerosis.” Journal of 
Cellular Physiology 173(1): 73-83. 
Weir, B. (1995). “The Pathophysiology of Cerebral Vasospasm.” British Journal of 
Neurosurgery 9: 375-390. 
Weisgraber, K. H. (1994). “Apolipoprotein E: structure-function relationships.” Advances in 
Protein Chemistry 45: 249-302. 
Weisgraber, K. H., A. D. Roses, et al. (1994). “The role of apolipoprotein E in the nervous 
system.” Current Opinion in Lipidology 5(2): 110-6. 
Zannis, V. I. (1986). “Genetic polymorphism in human apolipoprotein E.” Methods in 
Enzymology 128: 823-51. 
Zeiher, A. M., H. Drexler, et al. (1991). “Endothelial dysfunction of the coronary 
microvasculature is associated with coronary blood flow regulation in patients with early 
atherosclerosis.” Circulation 84(5): 1984-92. 
Zuccarello, M., R. Boccaletti, et al. (1996). “Role of extracellular Ca2+ in subarachnoid 
hemorrhage-induced spasm of the rabbit basilar artery.” Stroke 27(10): 1896-902. 
 97
